ࡱ> kmfghij'` bjbj{P{P S::<B.B.B.B.....8ʡV..(**~uH\^^^^^^$hM-.$m|$$B.B.*~ .$2 B.8*.~\$\z*z..2.*T" Vr^,6L<,dl2.2.x.L%I SWIII,jIII$$$$..$.9nh$9...nh...B.B.B.B.B.B.  Audreys Life Science Meeting Picks for Feb. 2010 (Jan. 31st Edition) ******************************************************************** Bio2Device Group, Tuesday Morning, Feb. 2, 2010 Topic: Molecular Image fundraising in a tough environment Speaker: Russ Singleton , Molecular Image Date and Time: Tuesday, Feb. 2, 2010, 8:30 10:30 am Location: TIPS Group Law Offices , 1000 Elwell Court, Palo Alto, CA 94303 Cost: Free No registration required. Topic Description Molecular Image is an early-stage personalized medicine company with a software technology which uses magnetic resonance and specific molecular data for predictive diagnostics in multiple sclerosis and other diseases. We have been in a quest to raise follow on financing this year after a successful bridge round late in 2008. We have not yet been successful and this talk discusses the company and the quest in this difficult environment. Speaker Bio Since July 2009, Dr. Russell M. Singleton has been President and CEO of Molecular Image. Dr. Singleton has over 25 years of transformational achievements in general management, marketing, strategic business development and engineering initiatives across medical device, life science and semiconductor capital equipment businesses. Prior to Molecular Image, he was GM of the SPECT Business Unit at Philips Medical Systems, responsible for driving a successful turnaround which has resulted a 17% improvement in market share and significant improvement in profitability. Prior to Philips, Dr. Singleton was VP, Engineering at Perlegen Sciences, a venture-capital backed personalized medicine company, and in the early 90s a VP, Engineering at Molecular Dynamics, a venture-backed life sciences instrumentation company that successfully went through in IPO. Dr. Singleton also had cumulatively 18 years at at KLA-Tencor, a semiconductor inspection and metrology company. At KLA, he had VP/GM responsibility for startup and turnaround businesses spanning instrumentation, software and consulting including the acquisition of three businesses and spin-off of another. He received his BE (Electrical) from Pratt Institute, and received his MS and PhD from the University of Illinois in Electrical Engineering. ******************************************************************* San Jose BioCenter, Tuesday Mid-Day, Feb. 2, 2010 Program: Planning for Your Drug Development Success: From the Bench to the Clinic Speakers:  HYPERLINK "http://www.sjbiocenter.com/event/ev_2010Q1-DrugDevelopmentSuccess.html" \l "rs#rs" Dr. Richard Slauter, Senior Director of Drug Metabolism and Pharmacokinetics, MPI Research, Inc.  HYPERLINK "http://www.sjbiocenter.com/event/ev_2010Q1-DrugDevelopmentSuccess.html" \l "br#br" Dr. Brian Rogers, VP of Toxicology, Pacific BioDevelopment  HYPERLINK "http://www.sjbiocenter.com/event/ev_2010Q1-DrugDevelopmentSuccess.html" \l "sf#sf" Dr. Stephen Frantz, Director of Business Development, Pacific Northwest, MPI Research, Inc.  HYPERLINK "http://www.sjbiocenter.com/event/ev_2010Q1-DrugDevelopmentSuccess.html" \l "db#db" Dr. David Brewster, Sr. Safety Expert for Global NonClinical Safety and Head External Relations, US, F. Hoffman-La Roche Date and Time: Tuesday, February 2, 2010, 12pm-2:00pm 11:30 AM - 12:00 PM Registration, Lunch, and Networking12:00 PM - 12:20 PMLeveraging Drug Metabolism and Pharmacokinetics in Lead Selection and PreClinical Therapeutic Development12:20 PM - 12:40 PMMoving From Research To Development: Avoiding The Pitfalls12:40 PM - 1:00 PMEffective Partnering with a Contract Research Organization to Optimize Your Drug Development Plan1:00 PM - 1:20 PMThe Role of Preclinical Safety Assessment in the Drug Development Process"1:20 PM - 2:00 PM Panel Discussion & Q&A Location: The San Jose BioCenter, 5941 Optical Court, San Jose, CA 95138 Cost: Regular Price: $30 Partners' Network: $20 BioCenter Members: Free (RSVP to Aurlie) On-site Registration: add $10 to the above Register online at http://www.sjbiocenter.com/event/ev_2010Q1-DrugDevelopmentSuccess.html Space is limited for this event, so early pre-registration is recommended to avoid disappointment on the day!  HYPERLINK "http://rs6.net/tn.jsp?et=1102937193466&s=5641&e=001VBobrBKBfDYqzeQ0DFvxoDazcM3wv6NYEt2L-Unk3c-Wpk-KRb1wDKoRVAC_OqyqmGUQIUy7FEJzqVfuDTXTDHU3K-fYnwrUqy8IPJJjsW2bcEhb9GAN7EKmVr_3gm_KuDJOobm8IjX2ZZ_a3-R_bZvjtWiFjyClJukYcCzuU8OXhXt7-qAc1A==" \o "http://rs6.net/tn.jsp?et=1102937193466&s=5641&e=001VBobrBKBfDYqzeQ0DFvxoDazcM3wv6NYEt2L-Unk3c-Wpk-KRb1wDKoRVAC_OqyqmGUQIUy7FEJzqVfuDTXTDHU3K-fYnwrUqy8IPJJjsW2bcEhb9GAN7EKmVr_3gm_KuDJOobm8IjX2ZZ_a3-R_bZvjtWiFjyClJukYcCzuU8OXhXt7-qAc1A==" \t "_blank"  Topic Description The discovery and identification of a new molecular entity (NME) and the application of research required to show a proof-of-principle for a therapeutic agent can be rife with pitfalls and prove extremely difficult to qualify a new prospect for venture funding or partnering with another pharmaceutical company. This event will include discussions around: Leveraging Drug Metabolism and Pharmacokinetics in Lead Selection and PreClinical Therapeutic Development Moving From Research To Development: Avoiding The Pitfalls Effective Partnering with a Contract Research Organization to Optimize Your Drug Development Plan The Role of Preclinical Safety Assessment in the Drug Development Process The session will conclude with a panel discussion to provide attendees with the opportunity for valuable exchanges with experts in the fields of drug development and regulatory toxicology. *************************************************************** CABS, Tuesday Evening, Feb. 2, 2010 Seminar & Round-Table: Investor Pitch: How to Get Funding for Your Great Idea Topic:  HYPERLINK "http://www.cabsweb.org/CABSweb/feventslist.jsp?id=82" \o "http://www.cabsweb.org/CABSweb/feventslist.jsp?id=82" Seminar & Round-Table:  HYPERLINK "http://www.cabsweb.org/CABSweb/feventslist.jsp?id=83"  Investor Pitch: How to Get Funding for Your Great Idea How to Lay Out Your Great Idea (canceled & combined into Feb 02 seminar) Date and Time: Tuesday, Feb. 2, 2010, 7:00 - 9:00 pm Location: Foster City Recreation Center (650 Shell Blvd, Foster City, CA 94404); Gull Room See  HYPERLINK "http://www.cabsweb.org/CABSweb/feventslist.jsp" http://www.cabsweb.org/CABSweb/feventslist.jsp for details ******************************************************************** CSPA, Tuesday Evening, Feb. 2, 2010 Topic: Venture Capital Outlook 2010 Panel: David Lane - General Partner, Onset Ventures Prashant Shah - Managing Director, Hummer Winblad Venture Partners John Steuart - Managing Director, Claremont Creek Ventures Hing Wong - Managing Director, Walden International Date and Time: Tuesday, February 2, 2010, 6:30 pm - 8:45 pm Moderator: Steve Bengston - Director, Emerging Company Services (ECS), PricewaterhouseCoopers Location: Pillsbury Winthrop Shaw Pittman LLP 2475 Hanover St,Palo Alto - (650) 233-4500 Registration:  HYPERLINK "http://cspa10vcoutlook.eventbrite.com" \o "http://cspa10vcoutlook.eventbrite.com/" http://cspa10vcoutlook.eventbrite.com More Info:  HYPERLINK "http://www.cspa.com/eventdetail.php?eid=20100202" \o "http://www.cspa.com/eventdetail.php?eid=20100202" http://www.cspa.com/eventdetail.php?eid=20100202 CSPA Premium Members or Full-Time Students Feb 02, 2010 $10.00 $1.24; CSPA Basic Members Feb 02, 2010 $15.00 $1.36; Non-members (sign up as Basic Member for free at www.cspa.com) Feb 02, 2010 $15.00 $1.36; Premium Membership + Event Feb 02, 2010 $55.00 $2.37 You can sign up as Basic Member for free at  HYPERLINK "http://cspa.com/member.php and buy $15" http://cspa.com/member.php and buy $15 ticket. Topic Description Many are probably still saying good riddance to 2009. 2010, however, seems to be an entirely different story. We have survived the abyss of the financial crisis; the stock market has rebounded; even housing prices seem to be ....at least not dropping. Will 2010 bring back the exuberance of the pre-crisis years? What sectors will be the darlings of investors? What will happen to IT and software in light of the excitement in Energy, anything Green, and now, health care? Venture capitalists have always been a barometer of things to come. In this first event of 2010, CSPA is proud to bring together a distinguished panel of VCs, and ask them to examine their crystal balls. Where will VCs put their money in 2010? What sectors are hot? What are not? What will valuations look like? What advice can they give entrepreneurs? As is now our tradition, we will begin with a presentation of the latest MoneyTree Survey* from PricewaterhouseCoopers. Join us for an informative and insightful evening as we kick off 2010 in high gear. * The MoneyTree Survey is a quarterly study of venture capital investment activity in the United States, conducted as a collaboration between PricewaterhouseCoopers (PWC), Thomson Venture Economics and the National Venture Capital Association. ************************************************************************************** Tri-Conference, Wednesday and Thursday, Feb. 3-4, 2010  HYPERLINK "https://chidb.com/register/2010/mmtc/hallpass.asp" \l "2" Register for a Hall Pass |  HYPERLINK "https://chidb.com/register/2010/mmtc/MMTC_HallPass.pdf" \t "_blank" Download Brochure |  HYPERLINK "http://www.tri-conference.com/exhibit_fplan.asp" \t "_blank" View Exhibitor List Your Networking and Educational Pass to: 3000+ Attendees from 40 Countries 150+ Exhibit Booths 75+ Scientific Posters 3 Plenary Keynotes 2 Days of Exhibit Hall AccessTri-Conference Networking Reception Vendor Theatre Presentations Poster Competition NEW! New Product Pavilion  HYPERLINK "https://chidb.com/register/2010/mmtc/hallpass.asp" \l "register"  INCLUDEPICTURE "https://chidb.com/register/2010/mmtc/register.jpg" \* MERGEFORMATINET SCHEDULE OF EVENTS WEDNESDAY, FEBRUARY 3 8:00 am PLENARY KEYNOTE: When Drug Research is Personal John F. Crowley, Founder, Novazyme Pharmaceuticals, Inc.. Mr. Crowley, a Harvard educated businessman, created and built a pharmaceutical company devoted entirely to finding a cure for Pompe disease. He will detail his journey through the labyrinth of scientific and business fronts, which lead up to a first-round clinical trial. In 1998, two of John Crowley's three children were diagnosed with Pompe disease, a rare and fatal neuromuscular disorder that affects only several thousand children worldwide. After his children were given months to live, and being told there was nothing to be done, John began his incredible journey to find a cure for this fatal disease. For more information please  HYPERLINK "http://www.tri-conference.com/keynote_bios10.asp" click here 8:55 am PLENARY KEYNOTE: Technology, Aging, and the Brain Gary W. Small, M.D., Parlow-Solomon Professor on Aging, Professor of Psychiatry & Biobehavioral Sciences, Director, UCLA Center on Aging, Director, Memory & Aging Research Center, Director, Geriatric Psychiatry Division, Semel Institute for Neuroscience & Human Behavior, David Geffen School of Medicine at UCLA New neuroimaging and other technologies are teaching us about how the brain ages and what we can do about it. Although memory declines as we age, medical and non-pharmacological strategies may protect brain health and improve memory performance. At the same time, innovation in digital technology is not only changing the way we live and communicate, it appears to be altering how our brains function. As a consequence of this high-tech stimulation, we are witnessing the beginning of a new form of the generation gap a brain gap dividing younger digital natives, immersed in the technology early in life, from older digital immigrants, who adapt to the new technology more reluctantly. This lecture will describe this current pivotal point in brain evolution and how we can harness the new technology and lifestyle choices to improve memory and brain function so we can live better and longer. For more information please  HYPERLINK "http://www.tri-conference.com/keynote_bios10.asp" click here 9:40 am 5:20 pm Exhibit Hall Open Drop off a business card at the CHI Sales Booth for a chance to win a Wii or iPod! 9:40 - 11:00 Grand Opening Refreshment Break in the Exhibit Hall 1:45 2:15 pm Dessert in the Exhibit Hall 4:20 5:20 pm Reception in the Exhibit Hall 5:20 pm Exhibit Hall Closes THURSDAY, FEBRUARY 4 10:30 am 3:45 pm Exhibit Hall Open Drop off a business card at the CHI Sales Booth for a chance to win a Wii or iPod! 10:30 11:30 am Poster Competition Refreshment Break & Raffles in the Exhibit Hall 1:45 -2:15 pm Ice Cream Refreshment Break in the Exhibit Hall 2:15 pm PLENARY KEYNOTE: Chips, Clones and Living Beyond 100 Paul J.H. Schoemaker, Ph.D., M.B.A., Chairman and Chief Executive Officer, Decision Strategies International, Inc.; Research Director, Mack Center for Technological Innovation, The Wharton School; Adjunct Professor of Marketing, The Wharton School Adjunct Professor, Wharton School of Business As information technologies and life sciences continue to converge, new business opportunities and challenges will arise for the field of diagnostics and beyond. This keynote reviews the deeper forces shaping the future of the biosciences, from social and economic to technological and political, including the stresses they will introduce for existing business models and healthcare. Not only will bio-convergence introduce new products, services and competitors, it may create entirely new industries on a scale larger than the computer revolution has to date. Several broad scenarios will be painted for the state of the biosciences in 2025 and the forces that might take us there, summarizing a multi-year strategy study conducted and supervised by the speaker at the Wharton school. Paul J.H. Schoemaker, Ph.D is an internationally renowned thought leader in the fields of strategy and decision making. He speaks frequently at conferences, offers seminars around the world, and has appeared on radio and television. He has shared stage billings with President Bill Clinton, Warren Buffet, Rudolph Giuliani, Jack Welch, Prime Ministers as well as other public leaders. He is a leading scholar and visionary author, an entrepreneur in both the business and the philanthropic sectors, and has been an adviser to more than 100 companies and non-profit organizations around the world For more information please  HYPERLINK "http://www.tri-conference.com/keynote_bios10.asp" click here 3:05 -3:45 pm Refreshment in the Exhibit Hall 3:45 pm Exhibit Hall Closes  Top of Form Register for your FREE exhibit hall access to the Molecular Medicine Tri-Conference!: Bottom of Form ************************************************************************************************ BioE2E Biotech Entrepreneurs Program, Wednesday Evening, Feb. 3, 2010 Topic: Important Early Steps in Setting up Your Business Speakers: Bruce Cohen, MD, Founder, President & CEO VistaPath Genetics Bill Starling, co-founder of Synergy Life Science Partners. Paul A. Stone, General Counsel and Chief Operating Officer, 5AM Ventures Date: February 3, 2010, Wednesday, 6:30 pm Location: Wilson Sonsini Goodrich and Rosati, New front building at 650 Page Mill Road, Palo Alto Cost: $25 Pre-Registered, $35 at the door (cash or check only) Register at  HYPERLINK "http://www.acteva.com/booking.cfm?bevaID=197330&CFID=14059760&CFTOKEN=28195627" http://www.acteva.com/booking.cfm?bevaID=197330&CFID=14059760&CFTOKEN=28195627 Advance registration deadline: February 1, 2010 Program Please join us for the first BioE2E event in 2010. We will have an in-depth discussion of the initial steps involved in settingup your biotechnology business to succeed. This session will explore some of the early decisions relatedto formation of the start-up entity - includingtiming, documents, and choice of entity. We will also explore strategies forallocation of founders' stock and composition of the board of directors. This event is the first in a new BioE2E series: the BioE2E Biotech Entrepreneurs Program. Through aseries of seminars, this program will discuss business, legal, and practicalissues facing today's biotech entrepreneurs and provide them with guidance andresources to help them focus their ideas and business strategies. This program will feature monthly seminars covering a wide range of topicsincluding: Important early steps in setting up your business Effective business plans Building your board of directors and board of advisors Protecting your technology University/Institute licensing deals Financing strategies - Angels, VCs, and Corporates Term sheets Partnerships and corporate licensing Regulatory strategies Exits Speaker Backgrounds Bruce Cohen, MD, Founder, President & CEO VistaPath Genetics Bruce Cohen has spent morethan 25 years in leadership positions in life science and high technologycompanies. He was the founding President and CEO of two early stage biotechnology companies: Cellerant Therapeutics and Acacia BioSciences. He alsoserved as Chief Financial Officer for GeneSoft Pharmaceuticals prior to itsmerger into Oscient Pharmaceuticals. In addition, he held senior positions inbusiness development and marketing at SEQUUS Pharmaceuticals and Baxter. Mr.Cohen was the President and COO of ViTel International, a privately held, pre-internet electronic messaging company and was a management consultant with Monitor Company working in the health care and high technology sectors. Mr. Cohen has an MBA, with distinction, from Harvard Business School,and a BA and MA from Tufts University. He was one ofthe founders of the Tufts Veterinary Schooland a co-founder of the Health Professions Information Bureau. Bill Starling Bill Starling is a co-founder of Synergy Life Science Partners. Additionally, Bill is Chief Executive Officer of Synecor, LLC, a business generator and financial incubator of new medical device companies. During his tenure with Synecor, Bill has co-founded and invested in five major medical device companies, including Synecor. Bill began his career in the medical technology device industry atAmerican Edwards Laboratories (Edwards LifeSciences). He was subsequently part of the founding management team and Director of marketing for Advanced Cardiovascular Systems, Inc. (acquired by Guidant/Abbott) and was a cofounder, Vice President and Board Member of Ventritex, inc. (acquired by St. Jude medical). In 1992, Bill was a cofounder, Chairman of the Board of Directors and President/CEO of Cardiac Pathways Corporation (acquired by Boston Scientific Corporation) and was responsible for raising significant capital from the early venture capital period through an initial public offering in1996. Bill is a co-founder of BaroSense, InnerPulse and TransEnterix and serves on the Board of Directors of InnerPulse and iRhythm. Paul A. Stone, JD Paul A. Stone joined 5AM Ventures in July, 2009 as General Counsel and Chief Operating Officer. In this role, Paul handles legal matters and operational aspects of the firm, with responsibilities for finance,human resources, information technology and facilities. He also assists in investment operations of the firm, supporting investor relations, existing portfolio companies and new investments. Paul has held management and operating roles at private biopharmaceutical companies. Most recently, he was General Counsel and Senior VP Intellectual Property at Ethos Pharmaceuticals, Inc. (Redwood City,CA), a company researching peptide therapeutics. Previously, Paul was Senior VP, General Counsel, and Chief Patent Counsel, at Ilypsa, Inc.(Santa Clara, CA), a company directed to non-absorbed pharmaceuticals in renal, metabolic and infectious disease areas, which was acquired by Amgen in 2007 ($420 million). Prior to Ilypsa, Paul was VP, Chief Patent Counsel for Symyx Technologies, Inc. (Santa Clara, CA), a pioneering combinatorial materials science company. Paul began his legal career as a Patent Attorney at Senniger, Powers, Leavitt &Roedel (St. Louis, MO). Paul received his J.D. from University of Wisconsin Law School (1995), and is licensed to practice in California, Missouri, Wisconsin, and at the U.S. Patent and Trademark Office. *******************************************************************_,_. Triple Ring Technologies, Thursday Evening, Feb. 4, 2010 Topic:Fluoroscopy and Angiography for treatment of children with Congenital Heart Disease: Current Use and Future Needs Speaker: Dr. Phillip Moore, director of the Pediatric Cardiac Catheterization Laboratory at UCSF Children's Hospital Date and Time: Feb 4, 2010 6:00 6:45 PM Refreshments 6:45 8:00 PM Presentation & Questions 8:00 9:00 PM Networking & Consultations Location: Triple Ring Technologies, Inc.m 39655 Eureka Drive Newark, CA 94560 (510) 592-3000 Register for free at http://new.contactbeacon.com/cb/prefs/reg.php?id=7882cd5e-96e0-48ff-802e-94c87cd12ae0 Topic Description Dr. Moore is internationally recognized for his research on MRI-guided surgical procedures. He specializes in the treatment of congenital heart disease and will discuss his work developing and testing new devices and procedures. An overview of current fluoroscopy / angiography equipment and it's use for the diagnosis and treatment of congenital heart disease. Examples of current lab configurations and there use as well as case presentation of common catheter based treatment procedures. There will be a discussion of current trends and potential future needs in the field of interventional catheterization. The inaugural 2010 event on Feb 4 will feature Dr. Phillip Moore,. ********************************************************************* Bay Bio Medical Device Breakfast, Tuesday Morning, Feb. 9, 2010 Topic: Company Valuation for M&A Moderator: Mark Weeks, Partner, Cooley Godward Kronish LLP Panel Speakers:  HYPERLINK "http://www.baybio.org/wt/page/MD_Valuation_Speakers" Jason Yip, Principal, Montgomery & Co., LLC  HYPERLINK "http://www.baybio.org/wt/page/MD_Valuation_Speakers" Jeffrey Gold, Venture Partner, Longitude Capital, Former CEO, CryoVascular Systems Time and Date: Feb. 9, 2010, 8:00 -10:00 am Location: Cooley Godward Kronish LLP, Palo Alto Campus, 3175 Hanover Street, Palo Alto, CA 94304 Early Bird Registration through Dec. 4: $10.00 - BayBio & MDMA Members, Bio2Device and Bio-X Affiliates $20.00 - Non-Members On-Site Registration, Dec. 8: $20.00 - BayBio & MDMA Members, Bio2Device and Bio-X Affiliates $40.00 - Non-Members Register at http://www.acteva.com/booking.cfm?bevaid=192797 Topic Description The valuation of a medical device company for merger or acquisition is not an exact science. Some of the many variables to be taken into consideration include the companys management, market share, prospects for growth, and potential market size. Tangible and intangible assets and financial track record will be evaluated, as well as the company's reputation in the business community. The motivation and goals of key players also come into play, and current market conditions and timing are factors. A panel of industry veterans will explore the valuation process for medical device companies, discuss case studies and provide practical answers to help you increase your companys valuation. ******************************************************************* Bio2Device Group, Tuesday Evening, Feb. 9, 2010 Topic: A molecular diagnostic company's journey from science to product - Providing the answer to the fundamental question - What type of cancer is it? Speaker: Deb Neff, President and CEO, Pathwork Diagnostics Date and Time: Tuesday,Feb. 9, 2010, 6:00 9:00 pm Location: TIPS Group Law Offices , 1000 Elwell Court,Suite 150, Palo Alto, CA 94303 Advanced registration is required see bio2devicegroup.org website for details a week prior to event. Cost: Fee for light dinner with range depending on timing of registration Event Details- Registration is thru Google CheckOut Early registration ends at 12:01 AM on February 7 Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins- if space is available EARLY-BIRD REGISTRATION ENDS at 5AM Feb 8. Topic Description Molecular diagnostic approaches, when developed using robust scientific methods and clinical studies, are emerging to provide valuable clinical information for physicians managing and treating patients with cancer. Deborah will share the challenges and successes of Pathwork Diagnostics along their path from science to product to commercialization, bringing an innovative new product to market that has real impact on improving patient care. Speaker Bio Deborah Neff is the President and Chief Executive Officer, and serves on the board of directors, of Pathwork Diagnostics Inc., a company commercializing innovative molecular diagnostic tests focused in oncology. She is a veteran of the life sciences industry, with a proven track record of commercializing successful new products and building market-leading global businesses. Deborah was previously the chief executive officer of Predicant Biosciences, founded to develop technology for use in proteomics based clinical testing. Prior to joining Predicant in 2003, Deborah served as president of BD Biosciences, (a business segment of Becton Dickinson), where she held a series of roles with increasing responsibilities during her 15 years at BD. As President of BD Biosciences, she led a high growth business that developed and sold biomedical research and clinical diagnostic products worldwide, with revenues of approximately $700 million in 2003. Prior to her tenure at BD, she held various management positions at Organon-Teknika Corp. and CooperBiomedical Inc. Her career began with technical and supervisory roles in the clinical laboratory at two major medical centers in southern California. Deborah has a BS in Physiology from UC Davis, and is a medical technologist with a specialist in blood banking, having completed graduate study in Immunohematology. She also attended executive business programs in finance, marketing and general management at Wharton, Stanford and Harvard Business Schools. She served on the board of Advanced Medical Optics Inc, and ForteBio, and is a member of the Dean's leadership council for the College of Biological Sciences at UC Davis. ********************************************************************** BayBioNEST Venture Spotlight, Thursday Morning, Feb. 11, 2010 Topic:A Sweet Deal: How to Attract Investors Date and Time: Thursday, Feb. 11, 2010, 8:00 am 10:00 am Location: Latham & Watkins Menlo Park Campus 140 Scott Dr. Menlo Park, CA 94025  HYPERLINK "http://www.lw.com/Offices.aspx?page=Offices&office=14" \t "_blank" Directions Attire: Business attire suggested Cost: Early Bird Registration through Feb. 9: $19.00 On-Site Registration, Feb. 11: $29.00 Register at http://www.acteva.com/booking.cfm?bevaid=193973 Topic Description Venture Capitalists and Angel Investors are still looking for good prospects despite the economic downturn. Understanding what they want, at what stage they want to invest and the difference between them can help start-ups form a successful relationship with investors. Join BayBioNEST for the first of our 2010 Venture Spotlight Series events and learn how best to attract investors and secure a sweet deal. The BayBioNEST Venture Spotlight Series is a unique forum that allows investors to speak directly to entrepreneurs in a reverse pitch format. Investors and experts have a platform to discuss their current interests, target markets, therapies and technologies, as well as the maturation level of investment targets. The Venture Spotlight Series is a breakfast panel discussion with time for Q&A and networking. ********************************************************************** San Jose BioCenter All About Science Series, Thursday Afternoon, Feb. 11, 2010 Topic: Effective outsourcing: Navigating hurdles and avoiding pitfalls in virtual drug development The panel will include:  HYPERLINK "http://www.sjbiocenter.com/event/ev_2010Q1-EffectiveOutsourcing.html" \l "kh#kh" Kate Hanham, Ph.D., President & Founder, Mentara, Inc.: Mentara is a consulting consortium of highly qualified drug/device discovery and development professionals.  HYPERLINK "http://www.sjbiocenter.com/event/ev_2010Q1-EffectiveOutsourcing.html" \l "rl#rl" Richard Lin, President, Explora Biolabs, Inc.: Explora BioLabs provides vivarium and pre-clinical in vivo contract research services.  HYPERLINK "http://www.sjbiocenter.com/event/ev_2010Q1-EffectiveOutsourcing.html" \l "fa#fa" Fred Aslan, M.D., Vice President, Venrock: an investor experienced in starting and running virtual companies. An executive from a company using the virtual development model. Date and Time: Thursday, Feb. 11, 2010, noon til 3:30 pm 12:00 PM - 12:30 PM Registration, Lunch, and Networking 12:30 PM - 2:00 PM Presentation & Panel Discussion 2:00 PM - 3:30 PM Networking Dessert & Product Show Location: The San Jose BioCenter, 5941 Optical Court, San Jose, CA 95138 Cost and Registration:  HYPERLINK "http://www.acteva.com/booking.cfm?bevaid=195685" \t "_blank" *Pre-registration closes on Feb 9th!* Regular Price: $30 Partners' Network: $20 BioCenter Members: Free (please RSVP to Aurlie) On-site Registration: add $10 to the above Register online at http://www.sjbiocenter.com/event/ev_2010Q1-EffectiveOutsourcing.html Space is limited for this event, so early pre-registration is recommended to avoid disappointment on the day! Topic Description Virtual drug development promises savings of time and cost in the development of new drugs and devices. In order to realize this promise, managers and executives may need to learn some new tricks! In this session a panel of experts with different perspectives on the virtual development experience will discuss some of the advantages and challenges of the virtual model. Immediately following the event, the BioCenter will host a Networking Dessert & Product Show, generously provided by  HYPERLINK "http://www.scientistsolutionsevents.com/" \t "_blank" Scientist Solutions Events"!. Attendees will be invited to join us to enjoy delicious desserts, fruit smoothies, and gourmet coffees! *************************************************************************** UCSC Ext. Bioscience Product Marketing, Thursday Evenings, Feb. 11 March 25, 2010 Course Description This product marketing and selling-focused course gives participants an in-depth look at product planning and research, marketing planning, and promotional execution practices in the bioscience industry. Topics include market research methodologies, information sources and applications relevant to product planning; the development of marketing strategy, product positioning and differentiated claims; and the creation of tactical marketing programs and activities to maximize revenue potential. Course activities include the creation of a preliminary marketing plan. The course is well suited for all levels of professionals in bioscience marketing research, product management, product sales, advertising, public relations, business development and licensing, as well as other related functions,such asregulatory, clinical and legal. Lead Instructor: Audrey Erbes, Ph.D., is a life science business development and marketing consultant withmore than 25 years of managerial experience in marketing and business development in the biotech and pharmaceutical industry. She was Executive Vice President and cofounder of Kowa Research Institute and held management positions at Syntex Corp. in market research, product management, strategic marketing and planning, and business development in the U.S. and abroad. Guest Speakers: Chris Mahoney, MPA, WebMD, is an expert in the use of secondary patient data for pharmaceutical marketing applications, consulting with companies ranging from large global pharmaceutical companies to start-up biotechnology companies and Alan Hirshman, Senior Principal, Commercial Effectiveness, IMS Health. Before coming to IMS Health, Alan was Vice President of Sales for SDI Health. At SDI he was responsible for West and Midwest sales. "Patient Adherence: The Impact on Brand Performance." Stanley Skrzypczak, M.B.A., Director, Managed Care Marketing, Genomic Health, has over 25 years of successful biotech and pharmaceutical sales and marketing experience, including product, managed care, clinical marketing and sales management. Topic "Product Management 101- Developing/Executing The Tactical Plan" Charles Versaggi, Ph.D., is President of Versaggi Biocommunications, a strategic marketing consultancy for biotechnology, pharmaceutical and medical technology companies. Topic "Building Value through Strategic Marketing Planning and Communications." Steven Wong, B.A., is a Senior Consultant at Plan A, a strategic marketing consulting firm servicing biotechnology and pharmaceutical companies. At Plan A, he has directed numerous consulting engagements, including opportunity assessments, complex population modeling, and therapeutic area. Topic "Market Research Information Resources." Additional Guest Speakers with Short Presentations: Tais Schmitt, Ph.D. currently pursuing a Certificate in Bioscience Business and Marketing at UCSC Extension, agreed to share her student project experiences for this course which she completed in the winter of 2007. Topic - Tackling the Marketing Plan Project. Debbie Donovan,Consultant at eGold Solutions, has worked on client side on products that served the ENT, Orthopedics/Spine, Ob/Gyn and Oncology surgery specialties atSomnus, Kyphon and Conceptus, Inc., and most recentlySenior Manager at Intuitive Surgical where shefocused onmarket development programs ande-marketing initiatives.Topic - E-Marketing: Activating Patients in a Web 2.0 World. Erik Haghjoo, Ph.D., Consultant in the Life Sciences division of Simon-Kucher & Partners, focuses on developing global pricing and positioning strategies for new and existing products. His project experience includes product launch strategy, value proposition, pricing and reimbursement strategy, and portfolio strategy. Topic - Role of Pricing and Reimbursement in Product Management Strategic Planning. Dates and Times: Thu 6:00PM to 9:30PM Feb 11, 2010 to Mar 11, 2010 Thu 6:00PM to 9:30PM Mar 25, 2010 Number of Sessions: 6 Location: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara Tuition: $700 (Early enrollment - $630 through Jan. 28) See details at www.ucsc-extension.edu/BPM ********************************************************************** Palo Alto AWIS, Thursday Evening, Feb. 11, 2010 Topic: Real-Life CSI Speaker:Cordelia Willis, Criminalist, Santa Clara County Crime Laboratory Date and Time: Thursday, February 11th, 2010, 7:00 pm 7:00-7:30 pm Networking and light supper 7:30-7:45 pm Announcements 7:45-8:45 pm Program 8:45-9:00 pm Discussion Location: PARC Auditorium,3333 Coyote Hill Road, Palo Alto RSVP:online HYPERLINK "http://www.acteva.com/go/pa-awis" \o "http://www.acteva.com/go/pa-awis" \t "_blank" http://www.acteva.com/go/pa-awis Topic Description Since the O.J. Simpson trial the public interest in forensic science has grown rapidly, non-fictionalNew Detectives and Forensic Files. Cordelia Willis will give us a glimpse into the real-life world of the crime laboratory, discussing the various types of analyses that they perform as well as providing examples of interesting cases shes worked on. Speaker Bio Cordelia Willis received her undergraduate degree in Music Theatre and Math and then went on to get two graduate degrees: a Master of Science in Mathematics & Statistics from Northern Arizona University and a Master of Forensic Science from George Washington University. After internships with the Tucson Crime Laboratory and the NCIS Cold Case Squad, she became a criminalist at the Santa Clara County D.A.s Crime Laboratory. Her duties there include crime scene investigation, drug testing, fingerprint processing, biological stain analysis, shoeprint and tire track comparisons, DNA statistics, CODISDNA database maintenance, and laboratory outreach. ********************************************************** Bio2Device Group, Tuesday Morning, Feb. 16, 2010 Topic: Would You Hire You? Speaker: Denise Pringle, Global HR Executive Date and Time: Tuesday, Feb. 16, 2010, 8:30 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Parking: On street and in NOVA and library parking lots across the street. Cost: Free No registration required. Topic Description Ever wonder what those recruiters and hiring managers think of your resume when they see it lying on their desks?. Can you imagine what a person who has seen hundreds, if not thousands, of applicants thinks when your resume arrives? How do they dissect each resume? What kind of knowledge do you need to posses to be able to read people from a virtual piece of paper? Well now you can know. This event is for participants who are looking for new opportunities to gain fresh insights into their resumes and interviewing skills. Speaker Bio Denise Pringle has held global Human Resources executive positions in high tech and life science companies in the Bay Area. She has worked on transition teams for mergers and outsourcing and has had responsibility for organizational and leadership development, driving cultural change, training, talent acquisition and rewards strategies. Denise has been an adjunct faculty instructor at San Jose State University, an invited speaker at a number of professional organizations, and is on the Advisory Board of OurExperienceCounts.com. Denise received her Bachelor of Arts in Social Sciences from San Jose State University. ************************************************************ American Council of Medical Innovation, Tuesday, Feb . 16, 2010 Topic: Best and Brightest Forum on Medical Innovation Date and Time: February 16, 2010, 10:00 AM to 11:30 AM Speaker Richard A. Gephardt, Former Majority Leader of the United States House of Representatives and Chairman of the Council for American Medical Innovation, Panelists: Steve Blank, Professor of Entrepreneurship, U.C. Berkeley, Stanford University and the Columbia University/Berkeley Joint Executive MBA program Jay Hansen, Political Director, State Building & Construction Trades Council of California Patrick Lee, M.D., Partner and Co-Manager - Health Care Fund, Palo Alto Investors Refreshments will be served. Location: Mission Bay Conference Center at UCSF, Robertson Auditorium, 1675 Owens Street, San Francisco, CA 94158 Cost: Free Register at  HYPERLINK "http://events.constantcontact.com/register/event?oeidk=a07e2p1bii828469128&oseq=a01igfm56wag0" http://events.constantcontact.com/register/event?oeidk=a07e2p1bii828469128&oseq=a01igfm56wag0  HYPERLINK "http://maps.google.com/maps?daddr=Robertson%20Auditorium,%201675%20Owens%20Street,%20San%20Francisco,%20CA,%2094158,%20US" \o "Driving Directions" \t "_blank" Driving Directions Parking Covered parking is available in the Community Center Garage, located at 1675 Owens Street. Cash or credit card payments are accepted at garage exit. Fees are $3.00 per hour with a $24.00 daily maximum. No overnight parking is available. Topic Description Join the Council for American Medical Innovation, the California Biotechnology Foundation, BIOCOM, and some of the "Best and Brightest" minds in California for a robust discussion about the serious challenges facing the United States in maintaining its global leadership position in medical innovation. Moderated by Former Majority Leader Richard A. Gephardt, the forum will feature life science industry leaders, academic scholars, researchers, business representatives and other stakeholders who have come together to shed light on how the U.S. - and California - can navigate through the economic downturn to stay the course as a global leader in medical innovation. For more information about the event, please contact Charlotte Phillips at charlotte@perrycom.com, (916) 658-0144. Brought to you by: The Council for American Medical Innovation,  HYPERLINK "http://www.americanmedicalinnovation.org" www.americanmedicalinnovation.org California Biotechnology Foundation  HYPERLINK "http://www.cabiotech.org" www.cabiotech.org, and BIOCOM,  HYPERLINK "http://www.biocom.org" www.biocom.org **************************************************************** CACO Workshop, Monday Afternoon, Feb. 22, 2010 Event Name: Preclinical Toxicology and drug safety: large molecules Speakers: Ben Marafino, Kathleen Meyer Date and Time: Monday, February 22, 2010, 12:45 pm 5:30 pm Location: Bay Area: Foster City Crowne Plaza Event fee: $1 for unemployed; For others, details available upon online login. Major Sponsor: (1)Pacific BioLabs Vendor show vendors registered to date: (2)Absorption Systems; IITRI Online registration and further details:  HYPERLINK "http://www.caco-ca.org" \o "http://www.caco-ca.org/" http://www.caco-ca.org Registration deadline: 2/18/2010 (it will close sooner if the seating cap is reached) Additional Details: www.caco-ca.org  HYPERLINK "mailto:Support@CACO-CA.org" \o "mailto:Support@CACO-CA.org" support@CACO-CA.org  HYPERLINK "http://www.caco-ca.org" \o "http://www.caco-ca.org/" www.caco-ca.org *************************************************************************************************************** FountainBlues Life Science EntrepreneursForum, Monday Evening, Feb. 22, 2010 Topic: Life Science Angel Investor's Panel: Trends for 2010: Show Me the Money: Resourceful Ways to Secure Funding for YOUR Life Science Company in THIS Economy This month's panel will feature: Facilitator Maria Walker, Senior Director, Venture Capital Practice, KPMG Panelist Zachary Antovich, President and CEO, Linkage Biosciences Inc Other Successful Life Science Entrepreneurs at all stages - your recommendations are welcome Date & Time: Monday, February 22 from 5:30 - 7:30 p.m. Location: Bay Cafe Clubhouse, 1875 Embarcadero, Palo Alto Cost: $21 members, $32 partners, $42 general On-Site Registration is $42 for members, $52 for nonmembers, or $124 for FountainBlue Ongoing membership and admission Registration: Please pre-register by noon on 2/19 using the PayPal link at  HYPERLINK "http://rs6.net/tn.jsp?et=1102963556443&s=1932&e=001cA-pp6-4eWhqnUsKGIH5wSJNyYqizwifnsYmNNt3T6ARvBsza2bUTiplNqC3EZJDrVnr35qZ0Nk_CHqaUNvl-5S3UQrAg3m_wxYzS4bzgTURJTJKBRAWZQ==" \o "http://rs6.net/tn.jsp?et=1102963556443&s=1932&e=001cA-pp6-4eWhqnUsKGIH5wSJNyYqizwifnsYmNNt3T6ARvBsza2bUTiplNqC3EZJDrVnr35qZ0Nk_CHqaUNvl-5S3UQrAg3m_wxYzS4bzgTURJTJKBRAWZQ==" \t "_blank" http://www.svlifescience.com. Audience: Life Science entrepreneurs, intrapreneurs and investors, no service providers please Topic Description Even if the economic projections are getting more rosy, ask anyone running an early stage company and they will tell you that times are tough out there! The life science industry has provided a ray of hope when the economy was at its darkest. Historically known as a slow-moving industry, it has also been more resilient and less impacted by the recent economic challenges. This month, we will feature a panel of seasoned entrepreneurs and investors who will share their thoughts and suggestions on how to secure funding for life science start-ups, from grant and government funding to angel, venture and corporate funding. They will share their recent success stories and help you brainstorm how to best position your company financing. Speaker Bios Zachary Antovich is president and CEO of Linkage Biosciences Inc. Prior to this role, he was an executive with Applied Biosystems and has held various positions with both Bio-Rad Laboratories and Life Technologies (acquired by Invitrogen). He also lived in Europe where he consulted with Genset SA. He began his career as a research scientist for Syntex Pharmaceuticals (now Roche Biosciences) where he developed early methods for RNA analysis from bone. Your recommendations for other successful life science entrepreneurs at all stages of development are welcome *********************************************************************************************************** Bio2Device Group, Tuesday Morning, Feb. 23, 2010 Topic: Stem Cell Biology: Progress, hopes, hypes and hurdles Speaker: Monica Ranes-Goldberg, Ph.D., BiotechTraining Consulting Date and Time: Tuesday, Feb. 23, 2010, 8:30 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Parking: On street and in NOVA and library parking lots across the street. Cost: Free No registration required. ************************************************************************************************************************ Northern California Chapter, ACRP, Wednesday Evening, Feb. 24, 2010 Topic: FDA Clinical Investigator Inspections Update and FDAs New Expectations for Investigators: 2010 Update Speaker: Liz Wool, CCRA, CMT, President and CEO of QD-Quality and Training Solutions, Inc,Board of Trustees, ACRP 2010, President, Northern California Chapter Date and Time: Wednesday 24th February 2010 6:00 9:00 pm (Limited Space: Register Early) Agenda: 6:00 7:00 PM Registration, Networking, & Dinner Buffet 7:00 7:30 PM Welcome, Announcements, OPEN MIC for job referrals 7:30 9:00 PM Educational Program Location: BioMarin Pharmaceuticals, Inc., 105 Digital Drive, Novato, CA 94949 Program Description FDA investigator/site inspections focus on the Investigators engagement, involvement and supervision of the study in an in-depth and methodical manner beyond what is stated in the regulations. Poor site performance impacts both the investigator and the Sponsor; Sponsors run the risk of not having their product approved (as happened this year to a Big Pharma Company). These FDA inspection findings will be discussed through case study examinations. Good News is available to all stakeholders in clinical research; in 2009, FDA published these expectations for Investigators in their Final Guidance Investigator Responsibilities Protecting the Rights, Safety and Welfare of Study Subjects. These requirements will be outlined and explained to ensure regulatory compliance, subject protection, data quality and integrity and ensuring investigational sites execute clinical trials according to FDAs current expectations Program Objectives: 1. List FDA references and key topics reviewed during investigator site inspections. 2. Identify current trends in FDA inspection of investigators and their staff. 3. Define FDAs requirements for investigator adequate supervision and on-going conduct of a clinical trial. 4. Determine if an investigator is overburdened per FDA standards - in the clinical research programs they are conducting. Speaker: Liz Wool is President and CEO of QD-Quality and Training Solutions, Inc, a clinical quality systems and training consulting firm that is headquartered in San Bruno, CA. Liz possesses 20 years in the product development industry inclusive of positions in biotech and pharmaceutical companies, investigational sites, CROs, and academia. This experience includes drugs, biologics and medical device clinical research. She has presented at industry meetings on clinical quality systems, training and Good Clinical Practices (GCP) for numerous professional organizations and industry training providers including the Association of Clinical Research Professionals (ACRP), Drug Information Association (DIA), Society of Quality Assurance (SQA), Society of Research Administrators (SRA) and FDANews. She is also a faculty member for ACRP teaching the CRA and CRC Certification Exam Review Courses. Further, she supports the National Institutes of Health (NIH) as a Peer Reviewer for Auditing Contracts. She volunteers her time to the Association of Clinical Research Professionals (ACRP) by serving on the ACRP, Board of Trustees, President of the Northern California Chapter, Editorial Advisory Board, ACRP Monitor magazine and Member- Global ACRP Membership Committee. Lizs article,Good Training Practice 101: A Primer for Employee Training Plans was published in the June, 2008 Monitor magazine, for the Association of Clinical Research Professionals (ACRP). She holds faculty appointments at the University of California, Berkeley, University of California, Santa Cruz and San Francisco State University in the Clinical Research Conduct and Management Certificate Programs as well as serving as a Program Advisor to the UC Berkeley program. Target Audience: Clinical Research Professionals Sponsor Organizations Study Site Investigators & Coordinators Independent Consultants Students of Clinical Research Academic Medical/Clinical Researchers Service Providers/Vendors Institutional Review Boards Quality Assurance EVENT REGISTRATION through Feb. 21 Register early to assure admission; at the event IF space available (+$5 nonmembers) http://acrpnet.org/ Northern CA Chapter NCC ACRP member Free ACRP member $10 Non-member $15 CBRN & ACRP CONTACT HOURS have been applied for through ACRP CONTACT HOURS PURCHASE through Feb 21 Contact hours purchase not available at the event http://acrpnet.org/ Northern CA Chapter NCC ACRP and ACRP member $10 Non-Member $15 Sign-in at event, attend entire event, participate in group discussion, Registration questions: Megan Markowski at megan@acrpnet.org *************************************************************************** Bio2Device Group, Tuesday Morning, March 2, 2010 Topic: Life Sciences Product Development - Weaving People, Processes, and Procedures Togetherfor Success Speaker: Larry Wray, Principal, Wray Consulting Date and Time: Tuesday, March 2, 2010, 8:30 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Parking: On street and in NOVA and library parking lots across the street. Topic Description Success in product development depends upon a blending together of three primary elements- people (e.g. individual and team dynamics), processes (e.g. science and technical considerations), and procedures (e.g. business and quality/regulatory requirements). The majorsteps inproduct development will be discussed, withan emphasison best practices and lessons learned to provide for optimal outcomes with respect to quality, time to market, and cost. Finally, five major trends impactingthe industrywill be discussed. Thefocus will be on life science tools, reagents, and diagnostics, butmuch of thisis broadly applicable to the life sciences industry in general. Speaker Bio Dr. Larry K. Wray has over 25 years of experience in the in vitro diagnostics (IVD) industry, having held positions in R&D, project management, manufacturing, and business development. He has held positions as Senior Director, Development at Celera; R&D Director at Ventana (now part of Roche); and various management positions in R&D, manufacturing, and business development at Abbott Diagnostics.He has been responsible forthe development and launch ofover 25 products, both immunoassays and molecular diagnostics, on of a variety of instrument platforms, which have included products for blood screening, abused drug screening and therapeutic drug monitoring, bone metabolism, anatomic pathology, retrovirus, and genetic disease, all withboth domestic and international registrations. In addition to building and leading product development organizations, he established the core hybridoma facility supporting all product development, themanufacturing organization for themolecular diagnostics business,and led the successful restructuring of the diagnostic division's manufacturing organization, allat Abbott. Heauthored the strategic plan and established the core reagents program at Ventana, providing the company with an internal capability to develop and manufacture critical product components.He also led the start-up of a new business venture for osteoporosis and diseases of aging at Abbott.Dr. Wrayreceived his PhD in genetics from the University of Texas at Austin and was an NIHpost doctoral fellow in human genetics at the University of Pennsylvania School of Medicine. He is currentlyconsulting with both start-ups and established companies in establishing best-in-class product development capabilities. ******************************************************************* San Jose BioCenter, Tuesday Midday, March 2, 2010 Topic: The Ten Mistakes That Senior Management Teams Make with Investigational New Drug Applications Date and Time: Tuesday, March 2, 2010 Agenda 12:00 PM - 12:30 PM Registration, Lunch, and Networking 12:30 PM - 2:00 PM Presentation & Panel Discussion Speakers Panel Chair: Debra Gosling, Account Executive, Liquent Regulatory & Clinical Services, Thomson Reuters Lorna Speid, M.R.Pharm.S., Ph.D., RAC., President, Speid & Associates, Inc. Tom Delisi, Senior Consultant, Liquent Regulatory Services, Thomson Reuters Kathryn Plank, Senior Regulatory Consultant, Liquent Direct, Thomson Reuters Click Here for Bio Jim Hilferty, Operations Manager, Liquent Regulatory & Clinical Services, Thomson Reuters Location: The San Jose BioCenter, 5941 Optical Court, San Jose, CA 95138 Cost & Registration *Pre-registration closes on March 1st at noon!* (See details at http://www.sjbiocenter.com) Regular Price: $30 Partners' Network: $20 BioCenter Members: Free (please RSVP to Aurlie) On-site Registration: add $10 to the above Space is limited for this event, so early pre-registration is recommended to avoid disappointment on the day! ********************************************************************** FountainBlue's Funding Road Trip, Friday, March 5, 2010 Topic: Your Companys Value Proposition Speaker: Bill Joos, Principal, "Go To Market Consulting" Date and Time: Friday, March 5, 8:30 a.m. - 1:00 p.m. Agenda for the 'Your Positioning' Workshop: 8:30 Networking and Registration 9:00 Welcomes, Thank Yous and Introductions 9:15 Top Ten Mistakes in Business Plans Your business plan is the most important document you'll write as an entrepreneur. It can be the ticket to funding, and interest from potential clients and partners. Learn what NOT to do so you can develop a hard-hitting, compelling business case for your company. 10:15 Break 10:30 Your Positioning Before you can pitch your company to raise funds or attract strategic partners and alliances, you've got to perfect your positioning. This session will provide you with a systematic approach to help you better determine your all important market definition and value propositions. This program features a hard-copy, walk-away tool that helps define these for a technology based start-up company and also includes powerful and practical techniques from market research pros to validate your customers' real pain points and the value of your painkiller. Participants will be taught how to use this tool which is based on a case-study example of a real startup 12:00 Lunch Break and Networking 12:30 Optional Working Session, with Feedback 1:00 Adjourn and Networking until 1:30 Location: Cooley Godward Kronish LLP, Five Palo Alto Square, 3000 El Camino Real at Page Mill, Palo Alto Audience: Early-Stage, Funding-Bound Clean Energy, High Tech and Life Science Entrepreneurs and Intrapreneurs, who have attended our October and/or our November workshops Cost for 2 Entrepreneurs: $80 for FountainBlue members, $90 for Partners, $100 General, $110 On-Site for members and $120 On-site for non-members. An additional fee of $4-$5 will be added for processing. Registration: Please pre-register by noon on 3/2 using the PayPal link at  HYPERLINK "http://rs6.net/tn.jsp?et=1102963438461&s=1932&e=001TbaOD-4e4PKxHObBWZK4F1uazCb2QcqKtPOsIqjJZe0uNMEkvDba9fIZzf6c7DYXxhEWDJ6xTNntEKQZPgbA_fAvk_kBSrk3rN6J9uue4Fai6q2zS6A8VsLMUZLSB9s_vbhxA5TFPqkX36sni0ebqA==" \o "http://rs6.net/tn.jsp?et=1102963438461&s=1932&e=001TbaOD-4e4PKxHObBWZK4F1uazCb2QcqKtPOsIqjJZe0uNMEkvDba9fIZzf6c7DYXxhEWDJ6xTNntEKQZPgbA_fAvk_kBSrk3rN6J9uue4Fai6q2zS6A8VsLMUZLSB9s_vbhxA5TFPqkX36sni0ebqA==" \t "_blank" http://www.fountainblue.biz/fundingroadtrip.html. Topic Description FountainBlue is pleased to launch its spring 2010 Funding Road Trip Series, the first of a three-month workshop series serving high tech, clean energy and life science entrepreneurs within Silicon Valley. Begun in spring 2008, our workshop series is designed to help entrepreneurs think through their company's offerings as well as the market opportunity, and then communicate that opportunity succinctly and compellingly to strategic investors. This first workshop of this spring 2010 series focuses on 'Your Positioning', with modules on top ten mistakes in business plans and positioning. Our April 2 follow-up workshop will focus on the pitch to investors and our May 7 workshop will feature presentations to angel and other investors. Speaker Bio Bill Joos is the principal of "Go To Market Consulting", based in Palo Alto, CA. He works with early stage startups, venture capital firms and their portfolio clients. Most recently he spent 6 years as the VP of Entrepreneur Development at Garage Technology Ventures, an early stage venture capital firm that he co-founded along with Guy Kawasaki. His reputation at Garage was that he provided their clients with effective, hands-on, action-oriented strategic and tactical mentoring and coaching. Bill has worked with literally hundreds of early-to-mid stage startups and helped them polish and clarify their messages and refine their fund-raising and customer presentations; but his contributions to them extended well beyond being a "Pitch Doctor". He has mentored and coached them in go to market strategies, revenue and pricing optimization, business alliances, business development, partnerships, and marketing. Over 15,000 entrepreneurs worldwide have attended conferences where Bill has been a featured keynote speaker on various entrepreneurial topics. He has held sales and marketing positions with a variety of companies, including IBM and as a VP of the software division of Apple Computer. See the 8/15/08 Fox Business story on Elevator Pitch: Entrepreneurs Keep it Short and Sweet, featuring Bill:  HYPERLINK "http://www.foxbusiness.com/story/elevator-pitch-entrepreneurs-short-sweet/" http://www.foxbusiness.com/story/elevator-pitch-entrepreneurs-short-sweet/ ********************************************************************** Biotech Bay Career Fair, Tuesday Afternoon, March 9, 2010 Event: Biotech Bay Career Fair Location: South San Francisco Conference Center Date and Time: Tuesday, March 9, 2010, 2pm to 7pm Register now at: http://www.biospace.com/jobs/seekersignin.aspx Event Description Looking for a new job? Networking with industry peers in an ever-changing work environment? Sectors include: Biotech * Pharmaceutical * Medical Device & Diagnostics Job seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, medical device and diagnostics companies in the Bay area. Who should attend? Candidates with a 4-year degree in the life sciences and a minimum of 2-years of industry related experience are invited to attend. Just register by clicking the button below. (Equivalent work experience may be considered in lieu of a four-year college degree. PhD and Postdoc candidates welcome.) What types of positions are available? Exhibiting companies are recruiting for positions in areas such as: QA/QC, clinical research, engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory affairs, and research. What companies will be there? Take the time to research what each company is recruiting for to see if you are a match. Most companies will be from the Bay area, but some will travel from other regions to attract top talent! If you cant make it on event day, you can still pre-register online to allow exhibiting companies to view your resume and contact you outside of the career fair. ********************************************************************** San Jose State University Biomedical Engineering Society, Tuesday, March 30, 2010 Event: Bay Area Biomedical Device Conference 2010 Speakers: Julian Nikolchev, Founder & CEO, Pivot, Inc. Rob Abrams, Operating Partner, Sanderling Ventures Tom Bauer, M.D., Ph.D., The Cleveland Clinic Foundation Larry Eiselstein, Ph.D, P.E., Exponent, Inc. Raj Makkar, M.D., Ph.D., Cedars Sinai Medical Center Jeffrey Lotz, M.D., Ph.D., Professor, University of California, San Francisco Date and Time: Tuesday, March 30, 2010, 8:00 am 5:00 pm Location: Engineering Auditorium at SJSU For details and on-line registration, go to: http://www.engr.sjsu.edu/bmes/2010Conference.html Cost: $195 Early Registration $245 Late Registration (After 3/17/2009) $275 Walk in registration $40 SJSU Students $75 Non-SJSU Students Event Description The Organizing Committee has identified and invited a set of outstanding speakers who will address several areas that are critical to the biomedical device industry. There will be presentations on interventional cardiology, device explants, corrosion of implants, intervertebral disc degeneration and regeneration, appropriate selection of animal models for clinical trials, regulatory affairs and entrepreneurship pertaining to medical devices. This event will not only cover technologically significant advances in the field, but will also serve as a networking opportunity. **************************************************************************************       PAGE 8  DATE \@ "M/d/yyyy" 11/21/2009   *.345:>?GHIwhR=(h4h^sCJOJPJQJaJnHtH+h4h^s5CJOJPJQJaJnHtHh4hO _CJOJQJaJhqEh$5CJOJQJaJ h4hz h4h8[hjBhqE h4h%]hqE5CJOJQJaJh4he%5CJOJQJaJh4hC5CJOJQJaJh4hAE5CJOJQJaJh4hC5CJOJQJaJh4hiCJOJQJaJ4I( ^ 56dgdgdgds"`gd^sgdO _$a$gdqEgd & ' ( @ L ] ^ h 5ǴǴǴǥ|dM>h^-hCJOJQJaJ,h^-hs"`CJOJPJQJ^JaJnHtH/h^-hs"`5CJOJPJQJ^JaJnHtHh0JCJOJQJaJh{}HCJOJQJaJh4h{}HCJOJQJaJh4h^sCJOJQJaJ$h4h^sCJOJQJaJmHsH(h4h^sCJOJPJQJaJnHtHh4hUCCJOJQJaJ(h4hUCCJOJPJQJaJnHtH   X[\Z[mnp-.0ŵŠŵŵŠŵŵŠŵŵŠŵu]/h^-hs"`CJOJPJQJ\^JaJnHtH,h^-hs"`CJOJPJQJ^JaJnHtH&h^-h0J6CJOJQJ\aJ)h^-h0JB*CJOJQJaJphh^-hCJOJQJ\aJ(jh^-hCJOJQJU\aJh^-hCJOJQJaJ,h^-hCJOJPJQJ^JaJnHtH#Nb$)*  yz{qrstد؞yddId4jh^-hs"`CJOJQJU^JaJmHnHu)jh^-hs"`CJOJQJU^JaJ'h^-hs"`0J-CJOJQJ\^JaJ h^-hCJOJQJ^JaJ h^-hs"`CJOJQJ^JaJ/h^-hs"`CJOJPJQJ\^JaJnHtH h^-h0JrCJOJQJaJh^-hCJOJQJaJ/h^-hCJOJPJQJ\^JaJnHtHPLkdi$$If0}}634aytrHLkd$$If0}}634aytrH $IfgdrH d$IfgdrHOPbPLkd;$$If0}}634aytrH $IfgdrH d$IfgdrHLkd$$If0}}634aytrH$* PHHHdgdLkd $$If0}}634aytrH $IfgdrH d$IfgdrHLkd$$If0}}634aytrH uHFjk! X 8!9!~!!!!!! 2( Px 4 #\'*.25@9gd? 2( Px 4 #\'*.25@9gdkgdugd0gdO _gdtFjk?鳧{j{V;$,h bhuCJOJPJQJ^JaJnHtH5jh bhuCJOJPJQJU^JaJnHtH&hxCJOJPJQJ^JaJnHtH h4h00JCJOJQJaJh4h0CJOJQJaJh05CJOJQJaJh eh b5CJOJQJaJhs"`CJOJQJaJ,h^-h uCJOJPJQJ^JaJnHtH<jh^-hs"`CJOJPJQJU^JaJmHnHtHu,h^-hs"`CJOJPJQJ^JaJnHtH ?@VWX  ! * 1 G W X *!+!7!8!9!ƻƻ͚͚͖ƖƖƖƖƖzqehxCJOJQJaJhxhxaJh^hx0JjvhxUjhxUhx&hxCJOJPJQJ^JaJnHtHhxhx>*B*phjhxhxU hxhx,h bhuCJOJPJQJ^JaJnHtH5jh bhuCJOJPJQJU^JaJnHtH#9!~!!!!!!!!"""""""z##ȱȱȝr^^C4hIhkCJOJPJQJ^JaJmHnHsHtH&hTCJOJPJQJ^JaJnHtH&h?CJOJPJQJ^JaJnHtH,hIh?CJOJPJQJ^JaJnHtH&hkCJOJPJQJ^JaJnHtH,hIhkCJOJPJQJ^JaJnHtH&hICJOJPJQJ^JaJnHtH/hIhk5CJOJPJQJ^JaJnHtHhuCJOJQJaJ!B"}""""5#L#z##;$$4%c%%%&&&" & F 2( Px 4 #\'*.25@9gdv 2( Px 4 #\'*.25@9gdk 2( Px 4 #\'*.25@9gd?##$$9$:$F$G$$$$$$%2%3%4%F%`%a%b%c%%%%%%%%% &!&-&ɛttthXtjhvCJOJQJUaJhkCJOJQJaJhvCJOJQJaJhTCJOJQJaJhIhkCJOJQJaJ#hIhk0J5CJOJQJaJ7hIhk>*CJOJPJQJ^JaJmHnHsHtH4hIhkCJOJPJQJ^JaJmHnHsHtH5jhIhkCJOJPJQJU^JaJnHtH -&G&U&V&W&}&~&&&&++, ,A,Ͽ埋taM9,h_J5PJ\nHtH'h_JB*OJPJQJ^JnHphtH'hkB*OJPJQJ^JnHphtH$hkhkCJOJQJaJmHsH,hIhkCJOJPJQJ^JaJnHtH&hTCJOJPJQJ^JaJnHtHhThTCJOJQJaJ hZUhv0JCJOJQJaJjhvCJOJQJUaJ+jhZUhvCJOJQJUaJhvCJOJQJaJhvhvCJOJQJaJ&&)'m'''A(((()H))))).*u****C++++gdO _ 2( Px 4 #\'*.25@9gdk+ ,@,A,q------.<.Y.l..4/ $Ifgd_J & Fdd$If[$\$gd_J & Fdd$If[$\$gd_J dd[$\$gd_Jgd7AA,B,,,,,,,,, - ---[-\-o-p-q--.....۩sffUfU?*jh_Jh_JB*PJUnHphtH!jh_Jh_JPJUnHtHh_Jh_JPJnHtH:h_Jh_J5>*B*CJOJPJQJ\^JnHphtH.h_Jh_J5CJOJPJQJ\^JnHtH7jh_Jh_J5CJOJPJQJU\^JnHtH*h_Jh_J5>*B*PJ\nHphtHh_Jh_J5PJ\nHtH'jh_Jh_J5PJU\nHtH.//0/1/2/3/4/5/G/H/]/^///R2S22222222247777777 8رs`Ss`h_JhG6PJnHtH$h_Jh_J>*B*PJnHphtHh_Jh_J6PJ]nHtHh_Jh_J5PJ\nHtH h_Jh_JCJPJaJnHtHh_Jh_JPJnHtH!jh_Jh_JPJUnHtH*jh_Jh_JB*PJUnHphtH*jh_Jh_JB*PJUnHphtH!h_Jh_JB*PJnHphtH 4/5/H/^/0225E;kd$$IfKs#634Kayt_Jdd$If[$\$gd_J dd[$\$gd_Jakdd$$IfF(U#p6    34ayt_J57s888 9(9=99 :G:>{AAAA)B$dd$If[$\$a$gd_JK$$&dPa$gd_J dd[$\$gd_J 8r8s88888 9 9'9(9<9=9b999: :F:G::;.A/AmAnAxAyA{AAAAAAA(B)B¯Ӟreh_JhG6PJnHtH'h_Jh_J5B*PJ\nHphtH/h_Jh_J<CJOJPJQJ^JaJnHtH!jLh_Jh_JPJUnHtH$h_Jh_J>*B*PJnHphtH!jh_Jh_JPJUnHtHh_Jh_J5PJ\nHtHh_Jh_JPJnHtHh_Jh_J6PJ]nHtH$)B*B+B,B;BBBB!C,Co_ZZZZUgdRDgd7A$$dNa$gd_J9kd1$$If(#634ayt_J d$Ifgd_JIkd0$IfK$L$-(#  !634-ap ! )B*B+B,B;BJDJEJ & F gd7Agd7AgdRD|D}DDDDDD#E%E&E'E̴gLg)Dj^1hZUhp B*CJOJPJQJU^JaJnHphtH5hyhp B*CJOJPJQJ^JaJnHphtH/hp B*CJOJPJQJ^JaJnHphtH8jhp B*CJOJPJQJU^JaJnHphtH/hyB*CJOJPJQJ^JaJnHphtH/hb!B*CJOJPJQJ^JaJnHphtH5h7Ahb!B*CJOJPJQJ^JaJnHphtH/h7AB*CJOJPJQJ^JaJnHphtH 'EuEvEwEEEEEEFFDJʲpU=U"U5h7Ah7AB* CJOJPJQJ^JaJnHphI}tH/h7AB*CJOJPJQJ^JaJnHphtH5h7Ah7AB*CJOJPJQJ^JaJnHphtH5hyhp B*CJOJPJQJ^JaJnHphtH#hp B*CJOJQJ^JaJphfff)hp 5B*CJOJQJ\^JaJph/hyB*CJOJPJQJ^JaJnHphtH8jhp B*CJOJPJQJU^JaJnHphtH0hZUhp 0JCJOJPJQJ^JaJnHtH DJXJYJJ*CJOJPJQJ\^JaJnHtHddd"e#e$e-e7eHeJe_eve{e~eeeeeeeeLfRfʷwcSFScS:墏hG_CJOJQJaJh&;5CJOJQJaJh4h/<5CJOJQJaJ'h4h/<5CJOJQJaJmHsH/hG_B*CJOJPJQJ^JaJnHphtH$h4h/<CJOJQJaJmHsH(h4h/<CJOJPJQJaJnHtH$h4h/<CJOJQJaJnHtH5hG_hG_B*CJOJPJQJ^JaJnHphtHh4h/<CJOJQJaJhxCJOJQJaJRfvfffggggggiiMpkplpmpppppp q!qqqqqֻueuXuXuCuC(jh4h&5CJOJQJUaJh5CJOJQJaJh4h!H5CJOJQJaJh4h&5CJOJQJaJh4h&CJOJQJaJh4hG_CJOJQJaJ/hG_B*CJOJPJQJ^JaJnHphtH5hG_hG_B*CJOJPJQJ^JaJnHphtHh/<CJOJQJaJh4h%CJOJQJaJh4h/<CJOJQJaJlpmpppp#q^q r-rrrpt vQvvwXz{c{e|,}>}%gdb:rdgdb:rgd&gd& [$\$gd!Hgdnp6gd%q r r3rZrcrrr vPvQvvvvvw wȷȷȤxhYJ:Jhb:rhb:rCJOJQJ\aJhb:rhb:rCJOJQJaJhr hb:rCJOJQJaJhr hb:rCJOJQJ\aJ hr hb:r0JCJOJQJaJh&CJOJQJaJh4h&CJOJQJaJ%h4h&B*CJOJQJaJph h4h&0JCJOJQJaJh4h&5CJOJQJaJ(jh4h&5CJOJQJUaJ#h4h&0J>*CJOJQJaJ w!w~wwwwww&x'xxxxxxxyylymy}y~yyyL{c{d{{{{{{{d|x||۴۴۴m\ hb:rhb:r0JCJOJQJaJ0jhb:rhb:rCJOJQJUaJmHnHu%jhb:rhb:rCJOJQJUaJhb:rCJOJQJaJhb:rhb:rCJOJQJaJ#hb:rhb:r0JCJOJQJ\aJ)hb:rhb:r0JB*CJOJQJaJphhb:rhb:rCJOJQJ\aJ(jhb:rhb:rCJOJQJU\aJ#|*}~()kl02ā %8޻޻ޖwgwWwWwC&h4h 956CJOJQJ^JaJh4h 95CJOJQJaJh4hS65CJOJQJaJh4hl5CJOJQJaJh4hb:rCJOJQJaJhb:rB*CJOJQJaJph333)hb:rhb:r0JB*CJOJQJaJph%jhb:rhb:rCJOJQJUaJhb:rhb:rCJOJQJ\aJhb:rhb:rCJOJQJaJ#hb:rhb:r0J5CJOJQJaJ%&9saq_$+STё \$gd gd  & F hh\$^hgd  & F hh\$^hgdd! \$gdp \$gdlgdlgdl89s_apq^(ȯȘjQ:j:-hp hp 0JTB*CJOJQJ^JaJph0h<hp 0JT5B*CJOJQJ^JaJph0hp hp 0JT5B*CJOJQJ^JaJph)hp hp B*CJOJQJ^JaJph,h4hlB*CJOJQJ\^JaJph0h4hl0J5B*CJOJQJ^JaJph)h4hlB*CJOJQJ^JaJphh4hlCJOJQJaJ&h4hl56CJOJQJ^JaJ (^_RYZ[ζqP9"-hp hl0JB*CJOJQJ^JaJph,hp h_`5B*CJOJQJ^JaJphAhp hl0J5B*CJOJQJ^JaJfHphq )hp hlB*CJOJQJ^JaJph0hp hl0J5B*CJOJQJ^JaJph,hp hlB*CJOJQJ\^JaJph/hp hl5B*CJOJQJ\^JaJph0hp hp 0JT5B*CJOJQJ^JaJph0hp hp 0JT6B*CJOJQJ^JaJph H΋ÌŌygR?&?&0h hl0J5B*CJOJQJ^JaJph%h hlB*CJOJQJaJph(h hl5B*CJOJQJaJph"h<5B*CJOJQJaJph-h hl0JB*CJOJQJ^JaJph,hp h_`5B*CJOJQJ^JaJph0hp hl0J5B*CJOJQJ^JaJph)hp hlB*CJOJQJ^JaJph,hp hl5B*CJOJQJ^JaJph&h<5B*CJOJQJ^JaJph "#$6*+9;Xŷ{i{R;{{R,h h 6B*CJOJQJ^JaJph,h h 6B*CJOJPJQJaJph#h B*CJOJPJQJaJph)h h B*CJOJPJQJaJph,h h 5B*CJOJPJQJaJphh h 0J5PJnHtHh B*PJnHphtH!h h B*PJnHphtHh 0J5CJOJQJaJ3h h 0J5B*CJOJQJ\^JaJphяRSTeмy_F1)h hlB*CJOJQJ^JaJph0h hl0J5B*CJOJQJ^JaJph3h h 0J5B*CJOJQJ\^JaJph,h h 6B*CJOJPJQJaJph)h h B*CJOJPJQJaJph,h h 5B*CJOJPJQJaJph&h<5B*CJOJPJQJaJph,h h 6B*CJOJQJ^JaJph/h h 6B*CJOJPJQJ]aJph ёWȒZԓ>ϔДBCOޘߘKLgd64$a$gdaUBgdaUBgdl \$gdlǒȒ KL͔ΔޘߘDzhhNh0;haUBhaUB5B*CJ$OJPJQJ\^JaJ$nHphftH2haUBhaUB>*CJOJPJQJ\^JaJnHtH8jhaUBhaUBCJOJPJQJU\^JaJnHtH)haUBCJOJPJQJ\^JaJnHtH/haUBhaUBCJOJPJQJ\^JaJnHtH(haUBhaUB5B*CJOJQJaJphhlB*CJOJQJaJph%h4hlB*CJOJQJaJph)h4hlB*CJOJQJ^JaJphߘKir̙͙י+E؜ٜSîu^u^K%h4h64B*CJOJQJaJph,h4h64CJOJPJQJ^JaJnHtH,h4h4\nCJOJPJQJ^JaJnHtHh4h64CJOJQJaJ$h4h64CJOJQJaJmHsH(h4h64CJOJPJQJaJnHtH+h4h645CJOJPJQJaJnHtH%h4h!HB*CJOJQJaJph%h4h&B*CJOJQJaJphLi͙FɚP؜ٜ8STџ A -DM gdQ+-DM gdQ+gdl \$gd64dgd64gd64џٟ*,48@AI\}ء*HRwyʸʦʦʦʕrbPbPbPbPb#hhQ+0J5CJOJQJaJhhQ+5CJOJQJaJ hhQ+CJOJQJ^JaJ#h1hQ+CJOJQJ\^JaJ h1hQ+CJOJQJ^JaJ#h1hQ+0J5CJOJQJaJ"h1hQ+5CJOJQJ\aJh1hQ+5CJOJQJaJ(h1hQ+5B*CJOJQJaJphh64B*CJOJQJaJph}ءHǢcY\n /sgdl -DM gd0( -DM gdQ+$-DM a$gdQ+ -DM gdQ+gd1-DM gdQ+ & F-DM gdQ+ŢƢǢҢӢԢ?@AMϼvaR;)#h1hQ+0J5CJOJQJaJ,jh1hQ+0J5CJOJQJUaJh1hQ+CJOJQJaJ)h1h10JB*CJOJQJaJph4j3h1h1B*CJOJQJUaJph.jh1h1B*CJOJQJUaJph%h1h1B*CJOJQJaJph%hh1B*CJOJQJaJphhh15CJOJQJaJhhQ+5CJOJQJaJhh5CJOJQJaJMN`abcj\զ ¨ñ{e{R{R:{:.jh1hQ+B*CJOJQJUaJph%h1h1B*CJOJQJaJph+h1hQ+5B*CJOJQJ\aJph%h1hQ+B*CJOJQJaJph h1hQ+CJOJQJ^JaJ#h1hQ+CJOJQJ\^JaJ#h1hQ+5CJOJQJ^JaJh1hQ+CJOJQJaJ,h1hQ+0J5B*CJOJQJaJph,jh1hQ+0J5CJOJQJUaJ@ABUbfhij{|ҿ}mWFm:h0(B*OJ QJ ph hZUh0(0JCJOJQJaJ+j4hZUh0(CJOJQJUaJh0(B*CJOJQJaJph%h0(h0(B*CJOJQJaJphh0(CJOJQJaJjh0(CJOJQJUaJ%h1h1B*CJOJQJaJph%h1hQ+B*CJOJQJaJph.jh1hQ+B*CJOJQJUaJph)h1hQ+0JB*CJOJQJaJph/:t}٪Vdy*+qqqqqqqYqY.jhgP7hgP7B*CJOJQJUaJph%hgP7hgP7B*CJOJQJaJph(hgP7hgP7B*CJOJQJ\aJph(hgP7hgP75B*CJOJQJaJph%hQ+hQ+B*CJOJQJaJphhQ+B*CJOJQJaJphh0(B*phh0(0JOJ QJ h0(B*OJ QJ ph jh0(B*OJ QJ Uph+ABCX  abqrs234ҿҿҿҿҿzgR(hmhmCJOJPJQJaJnHtH%hmhmB*CJOJQJaJph(hbVhm5B*CJOJQJaJph%h4hgP7B*CJOJQJaJphhgP7B*ph(hgP7hgP7B*CJOJQJ\aJph%hgP7hgP7B*CJOJQJaJph.jhgP7hgP7B*CJOJQJUaJph)hgP7hgP70JB*CJOJQJaJph23?ABTH78E {XѹJdgdAgdAgdmh^hgdmgdm \$gdm4OpӮ9DEزٲ@A{ԼqqVqC%hmhmB*CJOJQJaJph4hmhm>*B*CJOJPJQJaJnHphtH:jhmhmB*CJOJPJQJUaJnHphtH1hmhmB*CJOJPJQJaJnHphtH&hhuCJOJPJQJ^JaJnHtH/hmhmCJOJPJQJ\^JaJnHtH(hmhmCJOJPJQJaJnHtH,hmhmCJOJPJQJ^JaJnHtH{!VWXaйѹ۹/I23̶wwhwwhwhwha]J%hAhAB*CJOJQJaJphhA h4hAh4hACJOJQJaJ$h4hACJOJQJaJmHsH,h4hACJOJPJQJ^JaJnHtH(h4hACJOJPJQJaJnHtH+h4hA5CJOJPJQJaJnHtH2hm<B*CJOJPJQJ^JaJnHphtH2hbV<B*CJOJPJQJ^JaJnHphtH3zbBM/1ugdlgd4\n dd[$\$gdd gddo3HgddgdUgdh'gdUgdmgdA3Nvwx'E]^ce齫jWjBj)hUCJOJPJQJ]^JaJnHtH%hUCJOJPJQJ]^JnHtH+hUhUCJOJPJQJ]^JnHtH&hKkCJOJPJQJ^JaJnHtH,hUhUCJOJPJQJ^JaJnHtH#h:B*CJOJQJ^JaJph)hh'hbVB*CJOJQJ^JaJph,hh'hez5B*CJOJQJ^JaJph,hh'hbV5B*CJOJQJ^JaJphǽϽ׽߽ݿCDL1P15gt!<zñéx'h.hd5CJOJQJaJmHsH8hUhm<B*CJOJPJQJ^JaJnHphtHheznHtH#h:B*CJOJQJ^JaJph)hh'hbVB*CJOJQJ^JaJph#hh'B*CJOJQJ^JaJph)hh'hezB*CJOJQJ^JaJph*abk'L/1uȹȹȹȹȹȹr_J(h4hgW5B*CJOJQJaJph%h4h B*CJOJQJaJph-h9\,hdB*OJPJQJ^JnHphtH(h.hdCJOJPJQJaJnHtH5h.hdB*CJOJPJQJ^JaJnHphtHh.hdCJOJQJaJ$h.hdCJOJQJaJmHsH'h.hd5CJOJQJaJmHsHh.hd5CJOJQJaJ23:;kl{ 6KLef6}~ֿ}'hgW0JTB*CJOJQJ^JaJph-h4h0JTB*CJOJQJ^JaJph-h4hpG0JTB*CJOJQJ^JaJph-h4hgW0JTB*CJOJQJ^JaJph(h4hgW5B*CJOJQJaJph(h4hpG5B*CJOJQJaJph& 3;tl|6Lf7~{ \$gd>kgdXqgdl \$gdpG~Oz{j带mV=(=(h>kh>kCJOJPJQJaJnHtH1h>kh>kB*CJOJPJQJaJnHphtH,h>kh>kB*CJOJPJQJ\aJph(h>khXqCJOJPJQJaJnHtH"hXqCJOJPJQJaJnHtH#h>kB*CJOJPJQJaJph#hXqB*CJOJPJQJaJph)h>kh>kB*CJOJPJQJaJph.hc675B*CJOJPJQJaJnHphtH4hUh>k5B*CJOJPJQJaJnHphtH{0UVh')OP\"#jgdlgd>k \$gd>k^gd>kgd>kjk!"RSUV)N\ |}ɜqdI3I+h>kh>k>*CJOJPJQJaJnHtH4jh>kh>k>*CJOJPJQJUaJnHtHh>kh>kPJnHtH+h>kB*CJOJPJQJaJnHphtH(h>kh>kCJOJPJQJaJnHtH"hXqCJOJPJQJaJnHtH4h>kh>k>*B*CJOJPJQJaJnHphtH1h>kh>kB*CJOJPJQJaJnHphtH:jh>kh>kB*CJOJPJQJUaJnHphtH !"#ijDEìtaQ<0$h B*CJaJphhB*CJaJph(h th5B*CJOJQJaJphhZB*CJOJQJaJph%h4hZB*CJOJQJaJph(h4hZ5B*CJOJQJaJph%h4h>kB*CJOJQJaJphh>kB*CJOJQJaJph-h>kh>k0JTB*CJOJQJ^JaJphh>kh>kPJnHtH4jh>kh>k>*CJOJPJQJUaJnHtH'h>kh>k>*CJOJPJQJnHtH EP}Kb{; & F h\$^`hgd  & F\$gd \$gd gdlEJK #)abcz{:;Ͳͦ|kZI j7h%Bhh<CJUaJ jK7h%Bhh<CJUaJ j5h%Bhh<CJUaJhlB*CJaJphh h(B*CJaJphh(hB*CJaJphh(B*CJaJphh(h(B*CJaJphh&?`B*CJaJphhB*CJaJphh B*CJaJphh h B*phh h B*CJaJphݽ署h@ h7hv!hv!hv!0JmHnHuhIf0JmHnHu hv!0Jjhv!0JUhhjhhUh B*CJaJphgdlgd7gd7@ 00&PP/R :p^s/ =!"#$% Fz"9>3 EJFIFHHExifMM*bj(1r2i ' 'Adobe Photoshop CS3 Windows2010:01:12 09:29:35ޠW&(.HHJFIFHH Adobe_CMAdobed            h"?   3!1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw5!1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ?TI%)3ִ5I;?g`?7$j$@YJڍ ~hFܥIۚ;7;W~ݕ@{S`mb}b>.q}}$h݀yVO$興6LQo[I+L I$RI$I%?TI%)U2X>9ZL@""A uE}lmLMken]MtQC9۞Aq.;CZ>0wkgɡԪ8bu7712fcRI%eI.{;}:ya}{Y]+Gm>K7==exUysPQDtolI+ JI$STQ{Ɨh8&sƗ\w*I?$Z>z%Φ,nkm>?˹>9bMrlqBQHs,< rw乎9^K^]vz{`~ad쭡j.mo}/}OK_-Ύ,8oKEeO{x8Q)/F6h7I%a຾>=G-uԲϳͮq.m/z[{_ }]kjtdo$Wa;VwLέuWsń6kZl-ok+- Lhoi(DŽjVD5$ZM%$I)UZ]cdY',Ix_y8K]]9V̸b>YF'޳FnߢH.U"'Rgooobޑ*̟c!wܩp ! bsFR88L Ӭϱʹbvm^YMeXH 0s鵫ka=.1^XysCç%Gw5u/Tcͮt9'k$oNkgO>Q힃>H_>]Ծ`^^ƚ ω>>~[eﾜzumUV%<9ˇ?owOXޜ1imƮ]SJXZ[:O?]ҬŹ{IWh{GZu <fWN-Zs!t4t_+eXwT5s1m[K[}E#s봼KC762SLcfHŽH$k'U\lgoi˿+jӨ?\mJ"Ơȭ tyLwH{&vm8$z[L>Fڒ*U}sy.90/Jֵѡ,'¯ F9J#XSlC=cn]/YGC\;կf&-'"PIfƺ~cw8 Z,X[zmpe\ӣs HkLx0ǒk ׺AnO5ErAzu.=n~E]f#5~uL^k~K O̿#ֻjOus79VdFu&۫icېhZWE65Y}u֪Sn>mzoK&GѶ18/lzeÓ\Qs?PŨӸ8tSoW67#}ӕSNEe_3| nWJr~te5.pa{xmgz{?HE]G ܌tF k[k+}e4o}w~Ŧ&v=kZND[}ʱUoK6+!@r'7MN(SkwW{^o־[ 4yԭ}GYqӍ]|Jck&| ;B Gv]-#c@k\ZXR>FcUHIHAn^-%-'轿c p] @Anz<;Y7u+~q!̱<~]:=+m}AA 1MmV_5~_GEWhs:n^z~m{N8+hi{1M]=~Ogb*ԍ((' @:K`3P,ͪQt05{Gب5--?G}f>[6<:}aYԲ1$c\o+'>=?MMki`">э;߈]]gOr9bːd$˃V?԰Fph8V]iquWEUZ⩉rny2ZFW]c_L+f-އE.efQ ׍]EU:h Ie{]?xu~fQq/slDl4K{*ZApR}V{q3s:ClǬ 簝Toz$Ɩ $R,TI%-5x (Zcbp>SVWCǴMw=ռ%E?RW;Gu7Gz/zU<)}V>`t|Ȫτ<,,m.kٿm̹VT*Clȳk^ͫq%?տ ^K6N܋>Gf/7YhC!A{g5 R>)IOm>tv>;9e4d7X,u_՜#^=[Tܼ81Dϫe2{hcTI%)ed7H4S"1OYQddij'Ɨ6ǵq,!YTy۟W8MtmYg߯ #Vۗf>VQ6xs{1o?7g"s[k1NC\ߡe/Ecd?+d}5}.`khoZU8L~#11@S62u&.ƖXx[]6mdՏԬǢi.ɪ-cͮӷek+x#P v ɫWA_V[\(.9gc]5YR֓{{ެYoXͩVe] w '4Sizh˱hum{wz{?*<_ٷ1_}Du_8ܺXZ HTI"TI%)$IHۍ۝{jcnxZs"I%JRI$'3S)z5=0n6ֱe^8̣UiBl{y'~7KgfPqe5n6کKG=ґ ޏzv)k#֫+?[\'L-aznŠb{֐TI'!TI%)$IJI$RǏe{6[V]^ܻLS{= =gU\Ch cmemN1ԣ2b!v4/~iWPp8mkYcQil~'P{],am_]7݅oWoz{ď5Ws0ݍeOMFs\sj<$&G"QNxDm=;Z;;}o?b.q:eof>l 20N+JnrHJdI%"Photoshop 3.08BIM8BIM%\I' j(+(r8BIMHH8BIM&?8BIM 8BIM8BIM 8BIM 8BIM' 8BIMH/fflff/ff2Z5-8BIMp8BIM8BIM8BIM08BIM-8BIM@@8BIM8BIMgWps_DrugDevelopmentSuccessWnullboundsObjcRct1Top longLeftlongBtomlongWRghtlongslicesVlLsObjcslicesliceIDlonggroupIDlongoriginenum ESliceOrigin autoGeneratedTypeenum ESliceTypeImg boundsObjcRct1Top longLeftlongBtomlongWRghtlongurlTEXTnullTEXTMsgeTEXTaltTagTEXTcellTextIsHTMLboolcellTextTEXT horzAlignenumESliceHorzAligndefault vertAlignenumESliceVertAligndefault bgColorTypeenumESliceBGColorTypeNone topOutsetlong leftOutsetlong bottomOutsetlong rightOutsetlong8BIM( ?8BIM8BIM8BIM h8JFIFHH Adobe_CMAdobed            h"?   3!1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw5!1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ?TI%)3ִ5I;?g`?7$j$@YJڍ ~hFܥIۚ;7;W~ݕ@{S`mb}b>.q}}$h݀yVO$興6LQo[I+L I$RI$I%?TI%)U2X>9ZL@""A uE}lmLMken]MtQC9۞Aq.;CZ>0wkgɡԪ8bu7712fcRI%eI.{;}:ya}{Y]+Gm>K7==exUysPQDtolI+ JI$STQ{Ɨh8&sƗ\w*I?$Z>z%Φ,nkm>?˹>9bMrlqBQHs,< rw乎9^K^]vz{`~ad쭡j.mo}/}OK_-Ύ,8oKEeO{x8Q)/F6h7I%a຾>=G-uԲϳͮq.m/z[{_ }]kjtdo$Wa;VwLέuWsń6kZl-ok+- Lhoi(DŽjVD5$ZM%$I)UZ]cdY',Ix_y8K]]9V̸b>YF'޳FnߢH.U"'Rgooobޑ*̟c!wܩp ! bsFR88L Ӭϱʹbvm^YMeXH 0s鵫ka=.1^XysCç%Gw5u/Tcͮt9'k$oNkgO>Q힃>H_>]Ծ`^^ƚ ω>>~[eﾜzumUV%<9ˇ?owOXޜ1imƮ]SJXZ[:O?]ҬŹ{IWh{GZu <fWN-Zs!t4t_+eXwT5s1m[K[}E#s봼KC762SLcfHŽH$k'U\lgoi˿+jӨ?\mJ"Ơȭ tyLwH{&vm8$z[L>Fڒ*U}sy.90/Jֵѡ,'¯ F9J#XSlC=cn]/YGC\;կf&-'"PIfƺ~cw8 Z,X[zmpe\ӣs HkLx0ǒk ׺AnO5ErAzu.=n~E]f#5~uL^k~K O̿#ֻjOus79VdFu&۫icېhZWE65Y}u֪Sn>mzoK&GѶ18/lzeÓ\Qs?PŨӸ8tSoW67#}ӕSNEe_3| nWJr~te5.pa{xmgz{?HE]G ܌tF k[k+}e4o}w~Ŧ&v=kZND[}ʱUoK6+!@r'7MN(SkwW{^o־[ 4yԭ}GYqӍ]|Jck&| ;B Gv]-#c@k\ZXR>FcUHIHAn^-%-'轿c p] @Anz<;Y7u+~q!̱<~]:=+m}AA 1MmV_5~_GEWhs:n^z~m{N8+hi{1M]=~Ogb*ԍ((' @:K`3P,ͪQt05{Gب5--?G}f>[6<:}aYԲ1$c\o+'>=?MMki`">э;߈]]gOr9bːd$˃V?԰Fph8V]iquWEUZ⩉rny2ZFW]c_L+f-އE.efQ ׍]EU:h Ie{]?xu~fQq/slDl4K{*ZApR}V{q3s:ClǬ 簝Toz$Ɩ $R,TI%-5x (Zcbp>SVWCǴMw=ռ%E?RW;Gu7Gz/zU<)}V>`t|Ȫτ<,,m.kٿm̹VT*Clȳk^ͫq%?տ ^K6N܋>Gf/7YhC!A{g5 R>)IOm>tv>;9e4d7X,u_՜#^=[Tܼ81Dϫe2{hcTI%)ed7H4S"1OYQddij'Ɨ6ǵq,!YTy۟W8MtmYg߯ #Vۗf>VQ6xs{1o?7g"s[k1NC\ߡe/Ecd?+d}5}.`khoZU8L~#11@S62u&.ƖXx[]6mdՏԬǢi.ɪ-cͮӷek+x#P v ɫWA_V[\(.9gc]5YR֓{{ެYoXͩVe] w '4Sizh˱hum{wz{?*<_ٷ1_}Du_8ܺXZ HTI"TI%)$IHۍ۝{jcnxZs"I%JRI$'3S)z5=0n6ֱe^8̣UiBl{y'~7KgfPqe5n6کKG=ґ ޏzv)k#֫+?[\'L-aznŠb{֐TI'!TI%)$IJI$RǏe{6[V]^ܻLS{= =gU\Ch cmemN1ԣ2b!v4/~iWPp8mkYcQil~'P{],am_]7݅oWoz{ď5Ws0ݍeOMFs\sj<$&G"QNxDm=;Z;;}o?b.q:eof>l 20N+JnrHJdI%"8BIM!UAdobe PhotoshopAdobe Photoshop CS38BIMhttp://ns.adobe.com/xap/1.0/ &Adobed@ W1   0 @!#41"3$P2%A5&  !1A"Qa2#0qBR3 @brSC$cs4PDTdt%5Eeu !1AQaq0"2B@Rbr# Ⴂ3s$PC4cS%!1AQaq0 @P hjC_8B $ɳ &N 8Vǟm /n멏cC 8Sǝ 'MYӅxSgZUWaӸ Iɟּ8LG{ꙷ}k@]˱޷a`VZ֜p~GEz~"=u.:=5hAqeOk(B"T:Sσk6Ujg}C]`I&nej*׸fºccw{]%z>/G !s#X2,:If7ehFP<VαwihWs;CZtmJ`}q73+/boWk˧3\?? Y۷ K;>cw1 ޼qH~Hpql|'WjoYm {E}k8m暹Z-YV/%XqL9d W p|kw~<ӷ1`g~5Y֥/{ʶ-@EoʿaL0OaUo:zot<^_ '؟V]E*It{:Qm5 ѽ0罭p $XQ](wz~~/UkK ոq䟟6q O-.%lqKχ\-c=UR}A#G_=0nUzZY!g3c'Pz#q6=Rf|kJ"ؑ)lD6F 夺lzc>qOE)kg13mm4I`vYw6S~nw92UW,&]zMEr1 Jiל#xVt7d9f/z?et'~§e}2ȷ=oL./=Ybzp!>FCOq74kWoLOg9}GXyNeKKe:mo;p1>&i깧cɈ4³FO$Q-l6~C~[3:.ku>qs8 Dz])Jb?'WmhG܇7x_wM˼#ywj b1>gCUc$k^##gϬ ǐx΍bJo?0wvdK;iyﭸƱb;MsW3b)nߏLksg޷ffNqڝau];#xVzSS Jqx~ ?;q V>i9n{F׮fرTFꒂ5 r JX\33:Mq[UmQez +#}m,SśUN#ۆm[U߷W i[)Th\.WO"uk4 O>ҺK^IM#Μ"$*O6>_eeg+g1~'w*,7w m=NfhY4 2/{ؐhj`%ތ{]oH+e^VCaD_$Yaǻm דX]OZ2Ҹ5h6V{ v]{vr¬47fѴw?-]}gDn}U;CZُaDЁȨ%ec,*c]s,vnٰ,m1ixYSD[&Oi}YO^UHt./$A6ȯP$]vƤZ46Ur#Xy㭡Ox3@ a6a8g@{w;cwpr\Z"k6ۏ1vMy2J7F*d:6Ѽ}䏝}Gs@ysI4*,ÏҵDj^[}SLeYU';>o\1%8Iq/ͻ7UrLF?K]I6gi$+ +(IcXQն8.+]4N$+_՛[Ut:%`{L$vHV"fg˴-v#x?!m^滺 R+2<ŖTwt6:ƴ69vҵMor;y~g%>MS,ͬfVO4ULҲRGph9tƳKc}PS3i\qMDMi=)`ӐcB[LCQ~f*F#z ImT~mu&SңS\&wu;zDk%t^HOt#"i7u .oq!\߸Ch)VF'[|dwKss J-um%7"ɴrUۅ )Nbe0l*:< Ťrx˹ԤDAd3x~V"7'8sjùS:6ՇS2;Ukoni EX123*6m.1e&i}X#/1:'3K>rr92&9-eP\YQ(gf-5[Ia3Ĭ~stšC)-slhWT2Zdx0O%>jypR-΅aٳPڃcc-"8;Gײ#wrk\ҋ 2hdF|ե6ʽ#i_{{ey-hASbx9Rk8}fs%/-t]:/~+S\^n8krBi-d8rcUc{z/YQEe[rM*itq+s?p4R13\jA,<7'ml4c=fV5O{IZ#Drq7>y.:5[G4+̂L| 2+{(2=A8~ 'Ud!yfd9^ϵ7Or6vB*9xr-n"dzem;s0 C;rx^#8 l $홵9k+KuTWeֱmI1^[vE[]_~ۖ ^vep({f ᾁ*bhm}nsN.G4Ǖyvfďfz.eӯTJMo;>Xvq,6 .9$ʶJ>̥{sVQ;#h*샍-vcaT23QQ͟O"6 b[&qTje' ,Uj_cvڍmnEK]k`u^e9] aa6!0. [ ( Ūko-9&ՐgM#[:+yݑRbF aˊiLwpيҷ{z^7u %tN獐y+bx H͹hM,fPotg?O6Yo<"ý~t#`jYƷ~b܋p}ŵua7g3N4B$JW! "$SdzvǍj*X)WⴆY36g59ų6/g8Vjrncg48:ř P,9{p?<_KS`Q7*rPyf"Dt  XeQRgOD/BrdC tv9'/ m3$*~U64n"~ 2]T?Gg>^#Oc X2} dHz߬x~8'cYa%QҾ[<\~}/9y)9ϪgM}adnz{3;ZLi~oNu+dM68糸j4a;+@6^{`+t\Ѡc/"2F?ud9zZB5DkL]U;ײEzje} ^K=h$iq58ֹcAOd*T,W 'd+blP bT:9bV0=EJUVK~U}M3jC N'S=/]~xDteCؕGz u_<%>=:|tZlE)MO%!mYb w'SN{ߪ~.#Z֥=/Mu?]zK)p\5uw%!yxS~vCՂ ]wusY WnDU-AE]څ=af.E+%oMLbbSHF@Eɱi/\G&,ZJшu;Wa}*wݯrZ]C'-tr dķ-_RZ8 fvDȖPhה:F^N?u6kᬬ8ԃܪ% CZ8&A ;99 N?\V=M3pMM)uZϦ9`75vCز,#)HT4$c?oVYħX"5uuUѱIAѩ 4삹ѫ[ؐ3qlXGb-\#hX <=sjr,;<:.3H]K.qbϕō9(4/g`4jiQr.`"Sb<)o cSF}"协(zoĮG,{Ikz'sA!窉Ŧn1tc^}16h["F^!H Ϫ &[1ΓD+8 {utэd ?k')m} [K F$6G Ũk_sBX>ECrS/j"iF?t# 906nrj]ܵnBrOsqڅU\?뗑&'8kQi=J}г V x*!cgxEJJǖZN] j_ үiVNx"'̦B jgQz|0/pI|\ RTGʜ*[=0 Yt6DGnڄΛ<٫E?V0>VDT!2lZ͟qOB3 pJ:4k̃`8g:')6c ! _S;S%fD򕻂ERDyʕbg@K" BL]Mq/7u+,[+~s5QLf8/9`G-oVN!9=!i(tP8a#/1bvdPxL4{# բ0zM^u/ڸʺܩEEkm?2%~TaaSVGpp~~\iiќl] %J9Kl`)~^z fU r@:t}+l^~nnw֐|MӰʀJӂ8m_Z\BPn eEgq}Gf]}{8p wo0(m3yDv|RoR,P R޴pku\tm=qQЂR>#1~YPQPBE 7)8c-3iXgփּ?JAB-HUo:!E-승g2= u؟_[bt=qpm v^p6- mnH JO4? <87ͥ,-hKIW0ǔ|ptL]x]̪Cm/*D};JEӖz0Z0թ ن%::<;>eL# IrbpfCS]q$uyZNoԨfp>`S[Nj*q`bNyV9IVIuW,9F\p@gR̍2T2'=ɟ",ӭxzx^`ڬZOqs;b8jZBnoOb?HpJ@\" !sS`JbxE:@9pAi:PTs2c0'mDmRόY(JfR5EC 7OQSJ6R03+' Q#xj̾<8X;&ꏶ%J7h;lڤK3-*㔁vȫ]cL3YsRqJjHi#vGlxfS,:q^y`TS]~b aen+_d8o\DWl{vY auכmB9 TeZ}ݣpRO ky>/Izܡ1hr?^% #g~}u;#Ro#٥)1^īBURxfԳ(LRe8{H hNTj̆)k0b߼miCl.aF!n>c03ЧH=rd犯+X141R 纘}vuѾr'CB˝0n脶]Ǐ- NPN :>"ؔxgs #a셰LQToDŽ䒲x 5׻dTJj:LL(p bAc&^3+H)rAM%p Bҷ3:3:ySS}^( HEW9b_zv}:~5/h]jŗ'C Olxg<}U۲ #YK-#˟ehk}Щvzt+2Y#hÊ uT[ W)FƇ f-.=ހzbhxq[j!d8j}E?Gݗϔz&p\?YuR9-" {~C̒^sbNKs'd~ށPߗ 7)L-4M"٤r < ؘEpqY Pgղ@H!'bm[LR9 W~q^Ȝý: NcŤ/rOukSYY)#S<2hys8Ӽq&mf77Nuc+ryTSrnjb?coY,Y=6Vr#-agkܻO1SRĆ@l0@-Yeַ^AThb@qxb*.]CH0ǵd3d d#Ս};Ʀ~Q7Tg"@r#Z'DOiUoH[\|b'VyѪT:A X=ql{nzXGVgjsՂi{Te=K\)PSҿ2lWPg;Y,-6@B&0s#.?Kh Qz$K8ĮJQ dE#8^qtȤLMդ[q(9m5R4+ZaL C㍤x?ӎ6ԖY˦g/=ɣ/)/rG"ظϚSя^,'[WF =ȒaOd~ͰI-$%w&uDFyOnn{=c_Z3tZ v¶*WdmATptȳ3>Ύju6]BabR:78u_fgmgf;1)9_a-{'0;N[gq7}E_τ(jz֙~!ݴjT1!ZM)SIGTg}_d|',6kqeiW{K$OˈkYފFQӡ"#Z̘\ᆷCXm:͇e6m}qbZ.ԱYmֲ4';~j۔+vj i?;g}$Yb˦3HyGݷK 笄i!1 b1$VvLnѪ N(akVT ԛa2N:;mU1 #ώUG⪯DcaDc-1jX3-:{&&1|:WNGѴv(M͢.;QH0 OK#Zl$4;b~x1'Oul ⾣zqX2^l=0J"jtzL(>X3k6G a[1ȃ"ZtQiYO,l=E$^6h+p.R^*,f@r(x7Bb!SQ3 fLr8<'+ÞJ<A)41=⟫RCm0 $u6gyU`fpG#K#!Sv%AeOwOˌx8,.?2KdoVu̢ƭUW>l{]qXrs|E|3÷j4:[JB# Jz '(&rQ,ң34?dg"-cFû=RIlgô&1KLP C|Ďx4Xɫ'rV1۳osTcTAQ,DG(l[oNŪs YVgc=K4e|Y=}K.KB\$6 o6 J7'PXuه  Y/8珻{W&f~[g?F"xb+MVvֈg Z,W:c81]&{s'YwVY.c>q(oqlg2φ|pǔe,}kkSmrl}S ,Yqͤ|6t%وzxOf8ǵ>*@qk᷋)y4\~ F3f*l.mH_KgG8ʺq Q3.S㳪.zK/ :URok ONq+9'JϖQqiUBҺr">uhXIqz c8Yh/a@l)zԜJ+^S9ϬqŰ@u%1!ȄX]>w4 q˳V_);?u$*\:Z'.X-5ݷt[w$sXbf4ͅkӞ8D+?실&Xp8V.??xf?F|] 'O9skd1d~1Ϫ?g=>ZRZCծ阨pg>Wgck jt-ۍS2V/Qk.吏k|?*N076Z}28:rv@'g 2BwX:RbMYn"ρrGuVΚ 5L{UΡȳZvBy؏bCh#YկoBQcF)mČ)qT~7/HR9Ο'Y++M g'Ve\+剃 pS^/էO8{}:Qh4GCJ^( FX킁=tG,RQ|b~l7Fz @#uetr)X-/HH񏭎f?/ümr3uM>;fq̑MI?jg֩ ۔3<2\嚦˙@b W붼jxryGJX;NYt(8ҵUk*XqosֵZy vYEmjׅ|CXSrfl8`"fFsb xOoSߠ+F9GnjmpQ[$*]I(RY)vN>gdg~49bE,t\VOL\sR 7]V}oEZ#/)_+Uҏܲz;%nv 7&d%!,IٜLa!V}9U{\Z.>Lm^fK v`d'"n5O`Yj'/Ik&CML߂Ȇ8O-z?MPj6:4&4)EE:z q^ٽݴMҽrb$fpFyooXSktS'h/ӏ"?LcmTdki-ZXZ0/xޭԿJ4-VG^SaЈ)yGK-m;>Nk؋KK L;1LK,"P׭u^–.u9indP%#FyVPүd %n\ȗw93zpTSR$RP΁ZlHNR\&3O7+&;)YdRu7ֺdw- {HnHLTܗLM?K`ͣml7BA}}%۔F+E]؉udfS?:Fg,:6iW\/gQ) Y-] 9K`ݟSCfF`HxW9fxRw~--l1C<=E1{޼T|᝗gW:5RN%m [XJZc21 YCBs)3葟K(Vm8څT*{k~C"獫pMRuڶd&5'ތj^[%  fg؞WF[S,eP(}(¶]6Wԫ\MVPXv*wd6i {͑*~%z=^1 m#f454 V + BU(ڽ·lx$pc#,x<W8j 3]9a^}`k8\N,bKW5qe=nvb֬ Um۪GY]PH)FЍ.?6Wl jDz)\RjOg'XJgvWp%yDeW2[,>]fOxE1N4ά{0¬uq׏s5<]PÇ<J[%GazR-,1WEP:ЕEzK0DN(7/+4yd`zLbY=^cn`nT>:iJ>!=舉n6hn_9㿾mܟXAn["ڙʱsk"zߛ܊#RiS{Lz/凪V>L6(8f4Qkz=BN~iw.׋HJzm=']?2y>'i+Zn։c?Ds_wsgѿ`݈(Zˬ>,SrP#Um+@Mrs-l'C1>2UnXbzBNeݘ1ÄpK򸐅^ ӜNE 3}= ZX\igL'/gc tGr+Nd:ᶒ'sKSͯT߷1?,;cQ{URQ'\\3g:m6ۮSz]V'1smQ 4fqgLt+ S8"% HƢq˕ipݒ_)u=o^mw[)o?Tnf uGm6K_Ɋt+Ƨrk/ PgђiW]p- 9\6[>?uOݑ?N(~?׺YqFcy\>5mP՘kO`WHUIz[U}K@)~ՕN sst4 d-Gc9pAXfsNxYy *1111Lq1=?]Vշ0x>~?^ eOniB~-36幖_5)fcw8kVac YLw9^[i,ج,dюUލt#m1nMTYgm#(g\LĶBs[o7lꋌo:xjW<8 Fkܫ?a݌Kv`M!8FihGFee d;Xg>]CەhNBQ.Y9p,D/ؓЬ>?@~Zr,YSj9׀3ɶv.kn]UQ ˽BSlP[hx*4VϢD)1ofkz:6]D^| ;Fg D\R~e5oe!"Vr(Dkvd)2Be9X2q&Q1-C gōqls-iXD;G'W{HfٽSٗr6QIE3:{3j;V R ^+5bzRyD.EKcbٙcʲe9F+HUK-Y|`q#8&ҋ;3uDfh矆nZ6ƮZSf1)s7;n%hXtԴFg9;sAo.hg>ҟE&5vǫ׏-m,]aQ 7XHrbcӏ!) )3UZ2@U##sx®V2MѺDu>gfĕeV|T(UzZVQ/E-Rmf*4q#m֚-sˬSDN^TiR.OQc<&;'M5&bh\]iȺ]3Ik㎼īp d"J1j᫚뱡vTL%ױ!;'@XCDn/g.}qy*zU՗>} Q([&~nK D>&gB80x9S)1ml,콩x{-їd %nef^jvh$x^< Rze~,%HLLW6NmItq"‰ 12lc?GݔbBZy'P't1Cb$`ymW9=H)q)}rN- pX`5M, t@f j+bRg=F>.|Rn;ht6")ゴFX-HRCl^P 'P<6"e k `9371c4Q43_ǯYoHL'BKwc;Q\vEjAά#=LG;zxX#|&SFL9/ L#wNs"1DҤq58O8jH+e?FL= T \=ˌuцXg0ҡGo|m%2|cO#%̞G<  HNhnk*ȋjKDYi:Nl[QOlxyj?p<:LɓK52'NrTdZAW 縤9͡}'O=_%fԥԱ?AKd}F(mqMn0x/$ %'Ty:112) H`{dHBP#n_4`О/w䩄$gLlZ԰P"Vu.rI<kȊ+LNKei>;@SXV)! il_%Bϱ/]@FS HNd]qCkxI]&Ăju=ɉqHs&IwbΛSNaLA((|V KK8=p[8Ŀ_πnWQ܀+櫡 '#at OerBpVX kyBfb40'lM t hjkYf)ΙGWhb΃Ycx{O|P*lY0a$? |0ͧ2YSqI"|2( "6̀<w\Qߴ)m P2dHI1J/禙[v %,Fyhe D3 ."IMp|8φhd S $QHYS/u"-=W64_ ">CT 0v+*8_Q7k#b9:FTp)E`u@D.IBI7'ۂUc޺JF$Nec I@g38 Bw8$쎆0k|]nH;bf>1CA0:z͙Fؤ C;uk Q3YΓGL` %L0p*zc8Boi.MAcm92"0<˷MLE*skbg?g9zdx`v>@rθ>eAk;8)dd8eI<}H_2K7+Z!o/ cN 'SvK`஀XX (HT6F'ׄ58x?Ĩ j9ԊAӮAn1IWpVZh6Ɣ43'(HK*J*]ǩuJNx]NٞD0wreC^'_j{qՋK0mK^DjZH@e0=A:SQ6,4+zu|OD|SA3ezc҆+Bju^Ⱦ:FW_ɀ yj FnMUS`Xǖ9Mzf[eR6ęO(H+ls&iXOa0< P668lgLlc>ET8Yw࣢d$3GrBN0G2l|p2x5o㿮Go|щ\K( cM`Y>,ixNN,`ɛ@]#p,Ө]I[An.cLY}Jh0 O7(-Yʯ smiq8٥|ZX  bGUql3_ $2S} MQۑSHZ@sP"Vt0J%d]#هqƉ˧J$c'1 jSt%0Ӷ@o|'!vcdW"t/A:C- ah:5sJ@ޒW*w3vV3:^aʪ|.D7z{Q{dlw1ǫ czafp]u)zet=A:$hvyp;4O>Ֆ$lJ3MV⬏ Lr]8Mde"nD^EL$L=F[I9CȸI0SaWm(nz4y`겟59u3B<0o a:/yAg&g^baB ?&ɺR>ʐf㇤-)~/SZe= ʻFqg28㨐-TAWHajx_ J%nb:bjqBJR-a;Y*9*2?z=D=cyXʙVmG5j%>)мnKM_.w:&/"qw0ݱInaS+vsVfuOAKJ6W3dP1OS Y "FP8m)/l#0[LNy?{R/OTxQC1z"n:,`6Gggqѓ 1D8lA wx V5= y NS=&<ͬ8'rf$ Pt kgtsgka0v)df%A=p8EA2Ď+w@9O48e?8c(`C#]dɸ}P'PCudB}[Ϟ-d%}4C70Tn f ,ގ`ϨR_TJVЧ#Q't$ȑ[a#Ċɢ о\FoAL+FcHq>0xnavSN6XGO?%@Qf{Qp1`\LςdSɸnbNU2"11/I]r՝4+qb/茔6NoٞMJ6'A?!C8Hz{1 7n7뼄njqcwOO=zRTAJgϺg>Ovˑk}?^zۭ$^'E7^t (=,wv^1ERG< }GC8au//u@6p{ @; `쇬/&~؀R0ZnAZ1979;.0uT7LG|4<^o$˂OϹ;tcwPg1L#t{'ExW1'ׇoJ8oyC֟*=h&=XH_HxqXs+2p񖗃<0tѯ + <O )T\9c ߇FA"kGn}rF0$~yb%T<@H<^pIvBwA>zzO _+]܊Iv{|!6w v(Vqo>%A1|~Ľ2^/OO/Rtt&Wx NmOOTI2<'6/N 2o~dP8 ay@+ќSr ?@Ժ#o<5P5p+Gwu'؀/W_J/HK9W9455i!pZ(:']hNwFT4mfIݑŎ!CSθ -0]&lH`ck_?rT}]٧'^'\q<1;9kM>`DFD ,wawq4$/&@dz|s~'xʦ:挃#ծ۶>b%!z<^lsIdhV^dj~k!,YnM5]w"#"VW-L&+b[1ỵN\ ˑgAq߯~_60ɼL=}dhnSQsNӬ`T(4/{6T6`&*c"c)P,`0ډJ`1'g@ Y@yBjAЈ)oChSF1BlLe-W Np=5gv7t;+y~tMTXsC;87O0>/5xFw7&(0(רOLg-,O`+:pTp6N"gdEo;z97/{>B_gOPzKCASDݫ)m[ \#e jarP9#̹e( XNP\TwaxsB} AP+P%] H 6rG: "1/#4-֑ub7 Pv@ZGR+Uo& FGOE#dnc\k4o"p$T2'G_9#}N3[i7rtjlbDl0 [So0A4S(TrMI `j&V0&'Lq|MQ>,'Caㅈ=9;Vo?/ڿX6B74Q#j>XH?u MR<5lıPm_0FfͬF&~7#'5şK>q5=S~?h>P>w|~ A`yM= Kwzp i52yCpڳJ>(?l/ ȕ{|O1^~ Cb1x~nw ,y0XȺg<<aS>C2w`b`\"=7_ۉ*I׶B?ʰ22FE ÑdIM'L q*D}@_m*# f׌"XNB8xϿepocOg!'S$n(ogm.~q@F)K)N^W?!JMuָ:-W.@ٛ5,=r|}<},~'22'?iيUqX :~#03^cˢG[Eīө]` 1",|B@~shOug(;Az>cԲw.e献Hz/A;~@z|N pm/#?d`ge[W#>c^\e6ycu1xu{ j褀?7)uGy-[AS8 (1Uç/#h]*oɎp(0'Xtx%9Wz7qh%Ŕ: 8#瓒olnrE~&9fK}p<;Gh!ilu Au_ϡwM`{p`WZ gMrʑĩn2JHI"΃ +.D:C̅,}9:}x11оȼg=}7R%w0=~q#U0iE^=.XCT/F I4<?a]!R}𰅣v ܳsIXCqLڍ euJw@=U# 2Gpc5|9Fe=DE.\s_gX$x ;(Mtt@3[,VԮ@#Zb}Zڱ nD|2k!nZwbiגL؏x۝ȯ8#lGU"(Q,ӵs}0I>3[b f'r *7~?YO:[*T~ QckZ rGF͡7EzM=K,e_ b;0c4>% /_7!gܺr:s[=7 d= nK۸KGp\NK.bzq$h"T  U+~ެ|Y*RIFX?Ϸ*Jܣx~V;9paS$C )~ 91pZ$~_P)3!g9_3Pv>]lj|fȿ'3He>#h0F_.cA9:2_x&'&_+J;Zɝ~V\'P[ j{)&mxc9h< bpr VOlAlB sqVGI/dosM_o$ *'~I19>dqv\ߓHd ͝oUyUg^XI.& }̄pS?9U~~Ӏ|'_9#"dthqb'_r\;~'8_L~vI:~ ~1?F?1f{W=sO`!>іS!ٍ¯ 퓝MN~TJ Mo:7 [?6y:w' ub d^Y):ã$1:{TT~rQIwvgt<*tB@75_rр쩌>wǎ~^\~; GkD|䬅0^;Y39{Ԩ}JPĤqv^-2~鞃>:B b1<Ǩ'0?X}ZX쭟| ~r|'_ "wᓤO Mi@KQ*  ~a>"}#q$|9l _O-#Vj0 Q W!a%p=h`XaYbG(d M-)ZHFң-hŤ>R(g'oeT B3A,<o1=XzE-tqY~vA82gbFWG a5LJbd*ª^M /sfњ$}E#I &ǡmn"WDn>̘aY>);Eh%9\G!"(*(FVMLbTKC3b.IiH߷4j?gB*72 qn:U Xh$ r\s$]Έ䝋 fzf"Gd!D(xנp?AȢmCز& Lq1J.͸< wwh,p2۩D%}ۈ:oM͏/Zra'ePN@Hlq4X2ƒAX(RŶ`.vWI T&+FZͩ3%3 NQ-.G\hizs)(L\W-LlFX$ՖPm'h7VR?uWEuP9'KTS'uXu4QQdH&"ḵ%'xa՘XH8Bc ӑ'h?=XJ,Ikt$*,}4& )p{~þ0+)eC„[Ra{.G޼ FبđAU ;R %ۡkc;@?8Nr9 JAڈy2pao${ђ(6 A+ c.) &aF@7xK,qYGOQZQ)aM3EGal|jY3B@gUq&#Cbkc`āiHS{f8s;B1%U PT: \gĵD Pl[Nl FHH \ 81V BJ9I#N/] dY":m`\ C58@d1|~dHC4"eM!Bՙ"@ V=B1Hel#A.c8k[y\+S~CB)h61 DjFrgʧ!'\4oU#W`' +vc3X$;h ꠜ%ڄ0"iBN6V% $6" JEi"ģCv#_;ƨA<|FJ j#lN䄈&AOiSwp >B PO.oܾbD>BD_&QQq j!äz) @5 ٝ-S,SO&*n$"v8 lM:s'N}F%V~y ;gC {&??̟o2IϧXuS\Ha'F!m(ڙJpBUGLSѾ.|9 xP:<Dץ\~<2_gsǓ7%$BdfC!dOY}%31gcEX^L'IEAşˏG9kτX|[s7C*ݣwo=[X+R ɳQ_Ptd ;je%8=7Q4.4[ ݝ#I'8L׋z"-#b`s6$pΒ 0Bw\[2~S@*tZ|o&Wm(9,$4Mc7rTs d|QP aR. : 9ɴbP*`fuEH(]Cp nM8AY88B`t5J:Ea2ڜB(U0͇gxe(@J]yIr@VMʷq#7!X<*9>d"!b@\e)I)F$v0;r1j| ?- Cc)3m<Kl"+c`h`ŗ+7델F"ŷ ¥QF?ɵ 8".Ji!!d+w/BS$Gp Z+oLB&(u%c@L\ i2rmN$mK"S"H!VӱR@̶#Ԁ0k!t^' TEA:Zz4#/лORT8'0 d9ɆiCSFU@ /jV(!8r|I*scZEмbB5Mk !s5C<6MyʡRPm)U8`򊼽cDay`*f(ǕDEB 6@P[tAvHňɆ[4:r11*Ij$c]%8@H1@0Z ɬl FBJLz@r "QBrc %m t?Fm}h17fR73ęL; r8%hO[¼ RD3bRں[ npCG5[LAe2eYH2 C_I Ch/& E@@EӐZ'BC<zQ$=r 18)a;lv:Ȁ%JZQ2Be 4&[p"nYgˑ(b #4IΙ 8V Rm%D! `b$QC'GQ |Fge Hɔt]ǰLHqr[壸ԫ}M]{CQsI>`PZ`EQ0-MX 574M` ~ D& p1" 8)CHA5RDXT"^Wq`! ҫӼ(k Hx,am0[$S 8'DlroChN̆c#dQqJȽd?Wi_U,:ԹA~ )PFP\(7SD\Rpx/ yLA!T A) l2Y]p1_"y3*ۍYS p4D[j\ QUo&}4!GѬ|(Y9%(w(|n6dP b1n"8&b`脞r"Hb8l(3IYb*/W@xB GUo 0%+ 912)wXv% 9|  Of..37M}FsZAH: CJT+ "D0@hXPT"U GMb  1 dAa Dk&IH~y&q"C#}gLPǮ-$H)lǩ"%H=&š0*-E.eP0,gUIb Ì>P l+"D7UQڞOL^PM CG@,Dӏ5ļd vfBN QC߾zH:ŷSHH+XQL xbHAQI2FMBN%-nz YZ)spr<,`AL[$XS]Ɛ!A$ʈ2vN"`q4H v`k~DɆyȪ8Q I+JQ qIL2Q RaE/$9,HD8ڏQIR @{46Ź:gτ w7ߓbG i-Ĺ1Nf&Ip\GoBDL}zyRxGCxwbo/8BšK`- :G!-TV=BI . ]!/_# ŬàmM g8ojbO{3To6әTX^S% dԄ%$0\ X6 NDu(_#"@wE$2+X'ݱ6$1`9CD:ԪPْu)r/ rhCt, n!IMZ+0-Q p$ʉR& A8˘ђ7+@Bv'X!1 b4"rH;U1Pƀ߻ UAɑ~FoSa3q,>V쭑ˡN1F:`iHeCY*n2PP$BG(YN ;2MD/=@=#ep(>2!DnG;@r{wTX߯LVޥ۫6@_2= =܇Ր:d ] qBԮG0ds"{^LVRJd~s Jh~F7A^_ ~_aEh{""DIs(~DS&Cɡ9Y$05˖l`:׮Hppx3n,/[Y*B(#XSÉ8_˳pyLE "+ ܃!&7 )ܐxFO?:{b+"R)ać47MvD4#a.$رxi2 8#l;l$VoyګLzռҔH e5$#$$L~pr`QH`L79'@(-}0$}4? MÓ=+=CM_O k}̎7}} YT%N{Tt4Uc}Bk'2 Q'2cM$SaUJȽȼ^ ?(dNp :w8DSLa8M?A%$3(2uĎ1b[J7KF@å V]RsҀo"W\1JL¼TX(- gv@Ay #{p2Ys!c1]ZbQz}EejV.]ObiElzdZR4r_*Ǘ/? Rm(@2\&gS8 J@%œe7q(  8P7 +ͨq⏩;F4 Ǧ<('d+>AC`^M*d;~왐䤵ǴlFjٴG{ɩ7D&v (Cʥ2!XQl[ [N 2{R$D09Qܖ4DDJڳ )R Y`N'Ϳ>Aw` @4P®/}0DBP#b9f"PPȆg u`z#%#@yD*P^1Iw((MIR%O,(l* L'4@@ 7|7I뢧B0ᕡB! 1QYۃG ox ܀1"0rī#RRcǤAd,_4K`RU@L{zWDsq}Γ}9X1 (R#D&BB.B [3Ca`Z3pc H nk!a<%ASkBw)1gBI*Bd~IW`1jVaXȰ:aYO,k*\mA׌M֭M^ydK;5A S/2c0B7ťɯ2"`_0򉇤eƄ=? 'JV7/(ѐi!4h`*&8[v1NFPRH -˙2} -zᇠ( N(!"edI`2A05%֨.7kH'LO/eu -'`Dc# @3q*Z'K( \DSc"*NȶhT"Q"ͮ-y[)Rp4Q@+7uB2<(@PTO3mhx0K®([+9$xERŐ0W>> Ml2nx1 *~8t{zV [S#;CX(bRXhDÒ(Fd aqY lA1v!Tta $&:ġ< DIY[]oCE xN:G`HpQFJ ɇQD,Gu / @-y$F MtN=-M`y7<[:' ]d'EP 1dM}%hk-u!-% X@PL-+n GdiPh;d2ʩeX XaL\\nC#zzImx(r M 1xƫc4Q*SI3hS@| gHF$dsxT}氰Y}HC1w/0!L fP8é2"ѽ 2f5t8GŦ$jD  Y‚Vp OH'&V$^E2cW!(PuxNJCDDdNR`6 y!^ .A 1 哝#7"&,HD4;'^-dP {-TK]H* l r \^EB !4(j5D4d{6-;ݲBȣ&A!8K!ܵw%%]GM't7*X/Fa*i!6N4]3%\ i _m@ݥVDAl0…RF 8Eձ+"3Bщ9NEE"wv^b ʢq91 j*d C­^CeK[ABrYTE'|Ra)2;Sr9@ADStdx `08iJ(JĂ)c_p=e> _&D9rH *pq@(4 -D)hHK q#cc۰ L&!A$ AA115bjxTsx,N} UiK@Q#G%ji^Ox{~ACsf/VEII2b0먌n8!5M'2)@c(MlCڸ?3 )NS4b6؏tr"%?;%ĿI~Wu)3&;=%b `KDvh# uH:z/,`Ǭ❫zJl3큉ÃLt_R=ߐC?^0$ŧ)K.'_w% {ğ8 :^D2JW1룫u@v>uAyOtH^*'}?@P/b+'TW{>|o g;O SX vH[g1MLdI<4({|휡R2D W=UĝU(65A,*I)qAoo`hcs@!'|g] He҇5n5X"G<"ijd%;# .I[tJ %,*O.nV,OsM霞@6@a_" M Y$&S1Hix90oB7"~_=4uU0Cp ,eF'27+ D+4Q# #yraQ}.:ٝqq/SrŹG(b (-,iԤ԰jV8rhfU,ESLchLeQ%j Wā?,~ruQ@쟃2v.D?gc?sF{'% 0{oa$͓F  ~V .XyǦZ#%7U}0CO0]errǎǒR Ų55Yn3:LJ[ uY" *=I鈥 RNF2y~\ IgIх :rJY!gW*}Oc 27W9b^dWD{De6CDA:)c4I^"rnL(bzzbCz<5 PNG  IHDRddGxm4OsPT*5uBd4Q{8LAEJj)zw?8fRT .==^3;٦wi͡o-`v~izgqεHp8&ȺB\oN?н猛[נz{H̊֐Jm4ns^İDLz濤MvY6:=SsF7y1=@ZBU@ ?0kF8phA,ߍ3Ϝtxw x h7z+ga;8tكF&B|3{.u򜒶i!č31ypǎ7,@n2 x~$|N晢?L~cFנ=E0 t͹w2}3wk[;^-[ˤ71xӂo3*ͣo[+BP 8 *v,^ 1#dFcR䜜ZKlyL .+ [RďAB\PlX"H?tM'ƁBJR]:tJp%%3N~ƌiHNuB4{Q%[9))'I qJm1 d>3 >aF7d'Z(1_hؓJI# 8ڡ1ċ 7UQ^O206%`0ȖK<<F6/lj"wΖA@d= *{A7nY?HbX&đF-)#>}{NqBXX9[D>5uBW˖|=pt#?^p-BDnWͳkKck>3fLmoGVJ櫍ZIhV8r- ╝ݧvX W@X9Myq4i,8u̠q.담_:Ɂ?<ӄj$phSm71Avɜ@`vY!M}mN_p85DGa6iSz ׏89Mn>d߿Cܹm̝K$rVa ZС Ho!%y뙒e-BW]d+Tn=jk y82gB[\`׃:H1!\.ꘕUWɰ\8:7nxG͋ؖa Klw=|He~쌸%iMV$sIMKN`R5rI1kz-ӓT96[`l1&$CuB@d#S +gx[[J׷hNĚ߾nM [-+Xa88,kPE X? >I\ (۷o4@$@X0tOw1S$t $v#5pQejw;ƄމXF %s$seTx!XlaO0mEj&EYwޅK'M2 P.];ΈN1@wŗhfkxq/ I-xj:ڑ  >\+6T1H)@R{!>x\K Uܔ!h_w8Wg"nKrENJ2Ja̸})f!9!*bҵ?ѕkڢ)c4@the-&j' `8=b_gɐV GEc>{RJV] ʜ 8&e/Yq#3.,?q@ !ٴawOS;c6O% }6CJ73"fyE S OMJ6QB|9sc[rcN6E8? ǁRXF _C{qMqE \2Qbe%rm Jpnt KS|Xح[?S*Ңag뒖Vu*G{&1*Է--IVMm [N>tk%cWΧj?zıapȺ >E ١s ׭677_xm8YU9WoCd};եAӆ?S"!IwN>>GG4M}[{^]Y#0$+dpŭ1Ln!,, fikS1JW!쬬d nw7QB1Шˆɚ^nUJQy{cLOF! j Rn.}]"=AABQ6n۶)H1Zu8 oa~.F.4ѧԶ\\s\Dv}6,C "pISHLYn{ZsVfsmSmϝknk&6Sw(5RR2\RkY;)ë\QLBHRב f]d`röy0a AiՐ:KY}D֫]F7wV6KU_YJAs-~E2< #}ܥwIuVEwkRgem@6M%ĬHG·yJts[1 ֒ii}ӗi,ud"X_EC:UIʋ݅wl¹1ɳ(,02~սwd1Mn.^Sh_j9v N|zy"Dhv0_L:OE={d/V5%osZygV$o]>FWo|+i{:8-L}\.%1v{:Nف! D}s#4D.&Z)WW;4dmȳ^豼oy9ካ=(/l6Ujrk@ʜe\+GSWf%s1zbKp"Mpspqnl u)N$4]n/\ٶHA`{6={\~ gE=$ۅ{?+/.#l籊qoJܬ;I|OX-RkQGhcxgg3ܧn>6HB;9QDȧz:B(Ŀtu];|ᭊ$M 5 {ekd+dP\2scvUvII:5n-&$4pSn?Y:A]\g4z8Vv) cvXy;_N*Q6ZͣIENDB`F I. x;401ƕJFIFddDucky<Adobed       lK!1AQa"2qBRb#Ⴂ34Scd5!1AQ"a23qbrc ?,j&#Iӓ!'+Wk~Ӑՙty8) .pC\;T1\@,'$)ylHf|°f1&d - 4(s[U$,LA*xeP^UOT!R,rH):AKdTQulh) u1@5LTG)c쁊 Nܤ5Cl&bRHԐu+ ʐ7H%֫yQ>6rpLkiO|K4)ip <Ȕ DT.o EARc8BI{aPbuk0+RIڕN<0xqđO KSg yi̽N(Rsp]և6 t5MWlu =#齼PstZ׈^4))gJWu 5|=bV=;P?ܨa*ONXVZQA^i hɬ-yUVT5!K2=%2S5O!w(m23*!9"0#{nԋQqqr0u{M4S"O"q%=|U6|+P"r,r ]o6vmfgUͮ=qoZ;^sRֵ7+T=*OQm3"F#(r@lfM|:;U8{% yk)ߥjԁu[Hm39"cn}*RJ N 2y0Y)Tرelv*"MZ^=j#R[6ef.hPJQjHpnP]ʮG&F[ibt{,FPA?l! /+&eNr,U3k;קMh$ ȖSj&nz>Ti/PУй0.l2;둻nKJXc Æ/>20g҆ylY}X%זOWџ܎w>#3z_BO嶺~zuOGv|*}*|Ii$u%^FqGu|-,ĥ";:?=!t?g$$If!vh55#v#v:V }65534 ytrHg$$If!vh55#v#v:V }65534 ytrHg$$If!vh55#v#v:V }65534 ytrHg$$If!vh55#v#v:V }65534 ytrHg$$If!vh55#v#v:V }65534 ytrHg$$If!vh55#v#v:V }65534 ytrH1DyK /http://www.cabsweb.org/CABSweb/feventslist.jspyK ^http://www.cabsweb.org/CABSweb/feventslist.jspDyK 'http://cspa.com/member.php and buy $15yK Nhttp://cspa.com/member.php and buy $15Dd` Pt  c PAregisterRegister NowRyrcMw\d! FyrcMw\d!JFIFHHC  C   Dx 9 ! 17TW"2AwBQ#a$'3G!1A"246QRTcdqa3BC#$S ?Db!Ɠ}oZtZm6IIFRi93:.ׅMK a{͚?J%V+TJVm 6uRw-w_ ?}DޓgסZ.t"&?u|C]$' EzM~ ^ hSIOI&?w|/9M67z%N'A='^r/lsWo8KENzO_Q7p;yȾoI_-w: ?}DޓgסZ.t"&?u|C]$' EzM~ ^ hSIOI&?w|/9VibMwԣjM'(8NRVsQybANpχ+MRvT oªITܒpFO*OSע+I{ WgEѪW$ H"AD$ H"ٞKnѮg/W=W*OSסOx&}O"h+ÝnewVs8Ø'InP9&V,IM$!OOa4QI =v[juCbX$@ę(FAqkbm2\FenMX`8M$3sq@&E"!`,/Z2$hs3?.Wmzqy`ީ̭ȾIً~pQu[$0y*P]$@G?m^O wHb ibTqJ'sūAmygmc\CWT&e<$ bar'94xd=(ȩ) 4j8ʻbAؤ8[*\nr^|i`/1eJ%j3(F z0t橋 )2E*8?ˏQekNʣtðjj->]Ve-9Xvz\V[M}07tLP䭽w+$j,?}_(sa/Blҝ;QJq)Fyߩ{yE^wIR+Ex9r+4_mK(QUxGP%ZXg1m`z-؎t+jT'Q(&%D)0Fn!IGZҫGY,PVvsmAvً~pQu[$0y*P]$@G?M^O wHb Gĩ1>O787 3^WY~;OqsO*P3ʠL@(ŧR+{˯M[?(yw:đ{([h-6do o[O̊iY I0c2@{9*幞T!|S:,.PumU+TD-g۩1k;vUiʓi/a? lH5Jm,瑶6"iNscRUYiīAM<gp sҴ:9mu-U:[HDm6[ :nzlMRٴ瓝J]緵)i'],͝ 8&pKdTCH0zB:G#ͥi۬w{:5 DntnsG!iٹsOayS-Ը6ἜF=]l@dKQGA=R:`Y O:bB.Nh#p7Mʮ1ٞKnѮg/W=W*OSסOx&}O"h+D+sDav9Z:ɤm'HP,IP:21fZ(<{l x֎ѭӦHpo{ n'P] ʍ~.2zrFVn+[q%YZ\$J(>#dg=famLEn{6r7tJ|F>gDˋ1qDŽAa/s6Y~?)j(KTҢs0jMb .0,{Mo*~7*jYH-:Nk0kzVV3$"%Pa:gК1*>XxDé5+uj'6hp\ E'hjTۉuր?N X'N]ְ wuC  %R8K!m5W[ H"ٞKnѮg/W=W*OSסOx&}O"h+D-byԞÊrmj[<2 {b ULTRS!.ybf867hfWU3/n3wg_3o$;akju;1h+w=WY@T2ˑiE)S u"0 >:K#@sV,uaƴVRQ3#dtgZ5u.[,40s Otn^SgTTS5{<4g=//Iآ_̿K׻M_>ƿ-c#ISU\n .&T34:cbH4fٿ>kB7=zjVo m:sIYYeD-~}_ mm&rp흳z?r?g!zKOn'=/,fR H"AD$ H"A[u?x>/6v9}vMXڰOC[;fͷkmgB5LJK\ʔUe'\ )v%E]{k۰8onog]gZٯgSvUoS~7{SvUoÁ~7gy›MmWgN! n7m^{W8}:f|){ݶy__~{SvUoÁ~7gy›MmWgN! n7m^{W8}:f|){ݶy__~{SvUoÁ~7gy›MmWgN! n7m^{W8}:f|){ݶy__~{-a>7m5[tJfbn\SdJS+3)&}zaO,8xmalWfJmq9ko{^g]fo\UT$ H"AD$ H"Aم$$If!vh5U5 5S#vU#v #vS:V 65p5534yt_J_$$If!vh5##v#:V K6,534Kyt_J<Dd,  c :ANormalFax01C"l0<!-- function FrontPage_Form1_Validator(theForm) { var radioSelected = false; for (i = 0; i < theForm.prefix.length; i++) { if (theForm.prefix[i].checked) radioSelected = true; } if (!radioSelected) { alert("Please select one of the \"prefix\" options."); return (false); } if (theForm.First.value == "") { alert("Please enter a value for the \"Name Field\" field."); theForm.First.focus(); return (false); } if (theForm.Last.value == "") { alert("Please enter a value for the \"Last Name\" field."); theForm.Last.focus(); return (false); } if (theForm.Title.value == "") { alert("Please enter a value for the \"Title\" field."); theForm.Title.focus(); return (false); } if (theForm.Dept.value == "") { alert("Please enter a value for the \"Dept. Field\" field."); theForm.Dept.focus(); return (false); } if (theForm.Company.value == "") { alert("Please enter a value for the \"Company Field\" field."); theForm.Company.focus(); return (false); } if (theForm.Address.value == "") { alert("Please enter a value for the \"Address\" field."); theForm.Address.focus(); return (false); } if (theForm.City.value == "") { alert("Please enter a value for the \"City\" field."); theForm.City.focus(); return (false); } if (theForm.State.value == "") { alert("Please enter a value for the \"State\" field."); theForm.State.focus(); return (false); } if (theForm.Zip.value == "") { alert("Please enter a value for the \"Zip\" field."); theForm.Zip.focus(); return (false); } if (theForm.Country.value == "") { alert("Please enter a value for the \"Country\" field."); theForm.Country.focus(); return (false); } if (theForm.Email.value == "") { alert("Please enter a value for the \"Email\" field."); theForm.Email.focus(); return (false); } if (theForm.Tel.value == "") { alert("Please enter a value for the \"Tel\" field."); theForm.Tel.focus(); return (false); } if (theForm.Fax.value == "") { alert("Please enter a value for the \"Fax\" field."); theForm.Fax.focus(); return (false); } var radioSelected = false; for (i = 0; i < theForm.update.length; i++) { if (theForm.update[i].checked) radioSelected = true; } if (!radioSelected) { alert("Please select one of the \"Please check off request for faxes\" options."); return (false); } return (true); } //--> type="text/javascript"JavaScriptb}Lacb!c n}Lacb!cPNG  IHDRfsRGB@}0PLTEO&IWIDATcPܿH\7L , QB@ !lؠ y`&0Mhpb3IENDB`{$IfK$L$-!vh5(##v(#:V -  !6,534-p !W$$If!vh5(##v(#:V 6,534 yt_JDyK Ohttp://www.acteva.com/booking.cfm?bevaID=197330&CFID=14059760&CFTOKEN=28195627yK http://www.acteva.com/booking.cfm?bevaID=197330&CFID=14059760&CFTOKEN=28195627DyK ^http://events.constantcontact.com/register/event?oeidk=a07e2p1bii828469128&oseq=a01igfm56wag0yK http://events.constantcontact.com/register/event?oeidk=a07e2p1bii828469128&oseq=a01igfm56wag0DyK www.cabiotech.orgyK 4http://www.cabiotech.org/DdKxX  C &Abullet"@@bjc0-9~I?JU 6 njc0-9~I?JUPNG  IHDRLݨ PLTECE~ٿtRNS@*bKGDH cmPPJCmp0712OmIDATc5 evkIENDB`Dd F  3 "@@Dd F  3 "@@H@H Normal CJPJ _HaJmH nHsH tHR@R P Heading 1dd@&[$\$5CJ0KH$\aJ0\@\ P Heading 2$<@& 56CJOJQJ\]^JaJV@V #e Heading 3$<@&5CJOJQJ\^JaJJ@J ,X Heading 4$<@&5CJ\aJN@N | Heading 5 <@&56CJ\]aJH@H Pj Heading 6 <@&5CJ\aJDA@D Default Paragraph FontRi@R  Table Normal4 l4a (k@(No List4U@4 P Hyperlink >*ph4 @4 PFooter  !*W@* PStrong5\4@"4 PHeader  !.)@1. P Page Number@B@B@ r Body Text$a$ CJ(PJtH f^@Rf 6 Normal (Web) Kd\$%B* CJOJPJQJ^JaJph3ftH &Oa& )astyle12$Oq$ <:!spelleJOJ Dtitle<5B* CJPJ\aJphMtH BOB DtextxB* CJPJaJphtH JOJ Dbio d\$6B*CJPJ]aJphtH @O@ `header1CJOJQJaJo(ph>><O< `body1CJOJQJaJo(phfffO (#bhBOB (#sub1"5;CJOJQJ\aJo(ph'}.X@. (#Emphasis6]BOB ^e subtitle15OJQJ\o(ph W:O: ^eitalics16OJQJ]o(4O!4 ^ebold15OJQJ\o(lO2l C contentnormal#ddd[$\$!B*CJOJPJQJaJphtH `OB` u pagetitle $Kd\$%B*CJOJPJQJ^JaJphJotH "OQ" rgrame<P@b<  7 Body Text 2 &dxbOrb 7Default '7$8$H$-B*CJOJQJ^J_HaJmH phsH tH FOF / texttype1215<CJ\aJe@ cXFHTML Preformatted7) 2( Px 4 #\'*.25@9 CJOJPJ QJ^JaJnHtH,O, XF yshortcutsPOP XFbodytext-gray-f1315CJ\aJphQVU\O\ `msolistparagraph,dd[$\$B*PJphtH $O$ ]Mregblu"O" a1phJOJ 5 verdana14red/dd[$\$PJtH 2O2 5 link-external8O8 I\ small1CJOJQJaJo(HO"H  gmail_quote2dd[$\$PJtH FV@1F  MFollowedHyperlink >*B* phROAR {$ds4210567:>*@CJH*S*Y(\]aJphLOQL {$ds431*67:>*@CJH*S*Y(]aJphLOaL {$ds601*67:>*@CJH*S*Y(]aJphROqR {$ds4510567:>*@CJH*S*Y(\]aJphROR {$ds4610567:>*@CJH*S*Y(\]aJphROR {$ds4710567:>*@CJ H*S*Y(\]aJ phROR {$ds6210567:>*@CJH*S*Y(\]aJphLOL {$ds541*67:>*@CJH*S*Y(]aJphLOL {$ds551*67:>*@CJH*S*Y(]aJph(O( {$ds2415\(O( {$ds191ph^O^ {$ds271;567:>*@CJH*OJQJS*Y(\]aJo(phXOX {$ds411567:>*@CJH*OJQJS*Y(]aJo(ph^O^ {$ds291;567:>*@CJH*OJQJS*Y(\]aJo(phBO!B {$ds3915CJOJQJ\aJo(ph%*O1* `i arttext112OA2 `i arttext11boldFORF `i arttext111Edd[$\$PJtH :Oa: `ibodytextsmallboldNg@qN 9HTML TypewriterCJOJPJQJ^JaJ"O" usmall$O$ Xstyle1DOD .ored3#5CJOJQJ\^JaJo(ph33 O navy O Cds24n\@nC z-Top of FormM$&dPa$<CJOJPJQJ^JaJtH t]@tCz-Bottom of FormN$$dNa$<CJOJPJQJ^JaJtH :O: Cds23Odd[$\$PJtH O Cds5HOH Zy0 ecmsonormalQdd[$\$PJtH .O!. Zy0 underlineb1RO2R Zvtext-body-indentSdd[$\$PJtH 8OA8 Zvapple-style-span&OQ& italicsJObJ )>U story_titlesVdd[$\$PJtH (Oq( )>UboldgrayO 9sub*O* O appoutputBOB Oheading2Zdd[$\$PJtH >'> VrComment ReferenceCJdOd ](`careerfaircontentname1 67>*CJS*Y(]aJph:`dOd ](`careerfaircontentdate1 67>*CJS*Y(]aJph4O4 |ec_bodytextwht@O@ G default_dd[$\$PJtH @O@ /content`dd[$\$PJtH JOJ nP Char1 adCJOJPJQJaJtH LOA"L Table Contentsb$*$1$a$CJtHhO1h )66HHTML Preformatted Char$OJPJ QJ^J_HmH nHsH tH.OA.  C text1 text2pORp 33Program course title e$a$!B*CJ0OJ PJQJ aJ0phtH vO!bv 33Program date(s)f$da$.56B*CJ OJ PJQJ \^JaJ phtH lOrl 33Program course #g]^>*@CJOJ PJQJ aJtH lOl ^Program fee,dates,times h$da$5@B*PJphtH <O< Lerroridd[$\$PJtH @O@ <#style27jdd[$\$PJtH FZ@F B Plain Textkdd[$\$PJtH ,O, S bodysmlbld,O, S bodysmlitl&O& Sbodybld0O0 c dnnalignleftO thea8O8 tregqdd[$\$PJtH  O! treg1"O1" &Hstil5@`@B@ _> HTML AddresstPJtH XOQX _>epi-pagetitle1#5CJ%OJQJ\^JaJ%o(pheBOaB (I%careerfaircontentname4Oq4 (I%controltextbox>Oqr> TPa0xdB*OJQJ^Jph8O8 TA15B*CJ\^JaJph2O2 TA2B*CJ^JaJphLOL Z# body bold{gdp5CJOJPJQJtH  O mIhea1NON ; brownsmalltext}dd[$\$PJtH BOB caDbodybold~dd[$\$PJtH 6O6 0>controltextbox1xOx :\<Program x number$hd]ha$%B*CJOJ PJQJ ^JaJphtH BOB G,?apple-converted-space$O!$ Estyle4<>@qr< =XNTitleB*OJQJ^JphNOqrN =XNList ParagraphB*OJQJ^JphFOqrF =XN No SpacingB*OJQJ^JphFObF 4: eventtitledd[$\$PJtH ,Oq, 1 moduletext4O4 /rreg-mediumtext,O, /r reg-labelsO  il0O0 DX smallestfontHOH ) redboldtextdd[$\$PJtH JOJ bag ec_msonormaldd[$\$PJtH DOD 4westerndd[$\$ PJnHtHPOP )paragraphstyle2dd[$\$PJtH *O *  submitted>O > date-display-singleO!  PsmNO2 N r msonospacingdd[$\$ PJnHtH"OA " +=type1"OQ " +=valueOa  +=telBOr B vastyle5dd[$\$ PJnHtH.O .  blue_headerPO P O` q-detailsdd[$\$OJPJQJ^JtH (O ( Wbodymain.O . W bodysubheadHO H W bodymain1dd[$\$ PJnHtHHC@ H ; Body Text Indenthx^hRR@ R ; Body Text Indent 2hdx^hN NlYI emailstyle18CJOJQJ^JaJo(ph2O 2 L subtitle_blue:O : L text_body PJnHtH*O! * L main_menu(O1 ( Lpipe5ph(OA ( Pgtextblue$OQ $ \style9&Oa & \style10<Or < Pjboxdd[$\$ PJnHtHHO H Pj linktest2dd[$\$ PJnHtH>Q@ >  ] Body Text 3xCJaJ,O , 6nG bold-colorBO B ustyle2dd[$\$ PJnHtH&O & ustyle21DO D 7Atext5amdd[$\$ PJnHtH$O $ Q+cc-varFO F _Jabstractdd[$\$ PJnHtHBO B _Jstyle6dd[$\$ PJnHtHDDE0! '4I(^ 5 6    OPb$* uHFjk!X89~B}5Lz;4c)mA  !H!!!!!."u""""C#### $@$A$q%%%%%%&<&Y&l&&4'5'H'^'(**-/s000 1(1=11 2G26{9999):*:+:,:;::::!;,;i;;;<}<<w====]?_?@@@@,AFA~AAAAB'B>BDBEBYBBQE5F6FDFJSL_O\PPQQQRlRRRNUUUVVu@xxxxz{{}} ^_*‡Ç@ƈ7g~ɉ(CXpq>?QMN؏< %&8GHj•Õ@yP\G*6Қț˛ݛ |.oRdé{Vǯ @)WZWe5fg8{"*4I 7%O=hq~1S~/W-?U >?@ABE0000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000000000000000000000@0@0@0000000000 0 0 0 000000000000000000000000000000000 0 0 0 0 0  0 0 0 0 0 0 0000 0 00000000000000000 0 0 0 0000000000000000000000 0 0 0 0 0 0 0 0 0 0 000000000000(00P0P0P0P0P(0(00R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R00_]0_]0_]0_]0_]0_]0_]0_]0_]00000000j0j0j0j0j0j0j0j0j0j0j0j0j0j0j0x0x0x0x0x 0x 0x 0x 0x0x0x 0x 0x 0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x0x(0x(0x0y0y 0y 0y 0y(0x(0x0*(0x000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0  0 000@000@000@000@000@0@0@000 004I(^ 5 6    OPb$* uHFjk!X89~B}5Lz;4c)mA  !H!!!!!."u""""C#### $@$A$q%%%%%%&<&Y&l&&4'5'H'^'(**-/s000 1(1=11 2G26{9999):*:+:,:;::::!;,;i;;;<}<<w====]?_?@@@@,AFA~AAAAB'B>BDBEBYBBQE5F6FDFJSL_O\PPQQQRlRRRNUUUVVu@xxxxz{{}} ^_*‡Ç@ƈ7g~ɉ(CXpq>?QMN؏< %&8GHj•Õ@yP\G*6Қț˛ݛ |.oRdé{Vǯ @)WZWe5fg8{"*4I 7%O=hq~1S~/W-?U >?@ABE0000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0T 00000000000000000000000000000000000000000000000000000 0 0 0 00000000000000000000000000000000000000000000000000000000000 0 0 0 0 0  0 0 0 0 0 0< 0000 0< 00000000000000000 0< 0 0< 00000000000000000000000 0 0 0 0 0 0 0 0 0 0 000000000000(00P0P0P0P0P(0(00R0R0R0R0R0R0R0R0R0R0R0R0R0R0R0R00R00R0R0R0R0R0R000^]00^]00^]0^]0^]0^]0^]00^]0^]00000000j0j0j0j0j0j0j0j0j0j0j0j0j0j0j0x0x0x0x0x 0x 0x 0x 0x0x0x 0x 0x 0x0x0x0x0x0x0x0x0x0x0x0x00x00x00x00x0x0x0x00x00x00x0x00x00x00x0x00x00x00x0x0x0x0x0x0x0x00x00x00x0x00x00x00x0x0x(0x(0x0x0x 0x 0x 0x(0x(0x0)0(0x000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0  0 000@0@0@0@0@0@0@0 0000 ;;;>t?9!#-&A,. 8)BB|D'EDJ\XM]^dRfq w|8(ߘM+4{3~jE !&+4/5)B,CEJw^lp%ёL{ [ Z m  - zqs?W*9F V}A$$$$$ %%[%o%&&&/'1'2'R***///.9m9x9<&=u=VVVV9WFWii j o~oo&pppqlq}qcsss(wkww<B Ϛ0g؟,W/xУ*GDDXXXXXXXXXXXXXXXCXXXXXXXXXXXXXXXXXXXXXXXX ,7>!PmnR$z"9>3 EBb$(bzzbCz<5 TvR$I. x;401ƕ PR$eimE`f ]yR$DQo$w| VؾR$N25f[NRwL R$0 oA:0E1R$U c2M--Q\ B+IR$u!x O)*R$H9u4lSx$R$2 [qd.H+R,R$f FLͩfS @ m, (   e s `A4ps_DrugDevelopmentSuccess3"p f NA*ZDZDi_RegistrationButtonhttp://rs6.net/tn.jsp?et=1102937193466&s=5641&e=001VBobrBKBfDYqzeQ0DFvxoDazcM3wv6NYEt2L-Unk3c-Wpk-KRb1wDKoRVAC_OqyqmGUQIUy7FEJzqVfuDTXTDHU3K-fYnwrUqy8IPJJjsW2bcEhb9GAN7EKmVr_3gm_KuDJOobm8IjX2ZZ_a3-R_bZvjtWiFjyClJukYcCzuU8OXhXt7-qAc1A==yK _blankyK http://rs6.net/tn.jsp?et=1102937193466&s=5641&e=001VBobrBKBfDYqzeQ0DFvxoDazcM3wv6NYEt2L-Unk3c-Wpk-KRb1wDKoRVAC_OqyqmGUQIUy7FEJzqVfuDTXTDHU3K-fYnwrUqy8IPJJjsW2bcEhb9GAN7EKmVr_3gm_KuDJOobm8IjX2ZZ_a3-R_bZvjtWiFjyClJukYcCzuU8OXhXt7-qAc1A==3"http://rs6.net/tn.jsp?et=1102937193466&s=5641&e=001VBobrBKBfDYqzeQ0DFvxoDazcM3wv6NYEt2L-Unk3c-Wpk-KRb1wDKoRVAC_OqyqmGUQIUy7FEJzqVfuDTXTDHU3K-fYnwrUqy8IPJJjsW2bcEhb9GAN7EKmVr_3gm_KuDJOobm8IjX2ZZ_a3-R_bZvjtWiFjyClJukYcCzuU8OXhXt7-qAc1A==D i A*Þ..i_RegistrationButtonyK _blankyK `http://www.acteva.com/booking.cfm?bevaid=195685#" ~ j s :A  pmoore#" B S  ?rLUsDf\Te Tj]lTiyTfeat _Hlt252542266 _Hlt252542252 _Hlt252542253 _Hlt252478130 _Hlt252526686 _Hlt252526687 _Hlt2525380692registershowtop LETTER.BLOCK7 LETTER.BLOCK9 _Hlt252470468 _Hlt252470469_PictureBullets6 $99vgE@@@@@@@ @@6 $99vg4Errslu t4Ȃ uǂ vQ wxL yz {$U#|TY }C#~tj ?x <6 D!!$9x $l0#dľDili0#8x d8x  LQz Qz LQz L0   Rz 0# !   ) k v v ! #Tc > , L I  & _ |  0#x  !| | d9x \ӂ !{K#$"d""‡"Ç,"ćl"Ň| v Ƈ v LJ v ȇ< v ɇ| v ʇ\'#ˇ'#̇'#͇(#·\(#χT Ї чԳ ҇ ӇT ԇՇ̥և ׇL؇ه̦ڇ\PۇP܇P݇Qއ\Q߇Q~ ᇔ~ ⇔ ㇔D 䇔 凔 懔L 燔 臔 釔  ꇔL 뇔 쇔 퇔  L     L     L     L     L     L     L       L        L     L     L    T    T    ! "T # $ % &T ' ( ) *T + , - .T / 0 1   ddp{##_<_<s<~EEEEEEMM MNNNKOKOVOOOOO9R9RLRTRWRWWWWXXXxfxfgggg@h@hKhyiyiiiiiis9s9sCsFs}}\llmv~>>JQؔؔ <<ɘؘ͘ #""n\\ho߲++>FIVVa˿׿!!+. <<P[//8>;;E      !"#$%&'()*+,0-./123745689:=;<>@?ABCGDEFHILJKMNOPQSRTUVWYXZ[\]`^_adbcehfgiljkmnopqrswtuvx|yz{}~ ##oz####q<|<|<EEEEEEM"M"MNNNTOXOXOOOOOKRRRVR\R\RWWXXXXXffggggGh^h^hiiiiiiisAsEsKsKs}}ju}ˍˍIPUUFFȘ̘טޘޘ"((33xƜƜgntt<DHNN_ccǿտ)-33OZaa7=HHDDE    !"#$%&'()*+,./0-123567489:<=;>@?ABCEFGDHIKLJMNOPQSRTUVWYXZ[\]_`^acdbeghfikljmnopqrsuvwtxz{|y}~ =*urn:schemas-microsoft-com:office:smarttags PlaceName=*urn:schemas-microsoft-com:office:smarttags PlaceType>*urn:schemas-microsoft-com:office:smarttags PostalCode:*urn:schemas-microsoft-com:office:smarttagsStreet9*urn:schemas-microsoft-com:office:smarttagsStateB*urn:schemas-microsoft-com:office:smarttagscountry-region;*urn:schemas-microsoft-com:office:smarttagsaddress9*urn:schemas-microsoft-com:office:smarttagsplace8*urn:schemas-microsoft-com:office:smarttagsCity Hr (@N]^h-/   M X ` k Zc{7B)0GN}z9;F5">"""''P(U($)))**,+9+++,",f0i011226666V;_;+<2<@<F<)>2>>>>>????@@Z@f@@@AABBBBBCVC_CxCCCCCCCCCC"D,DmDuDDDEEEEEEFF(G/GGGGGGHHHFJOJQJ[J`JlJJJJJKKM"MMMcNiNNN(O0OCOIOPP3R8RcVjVkVrVyWWWWWWNXTXXX$]+]J]R]_]v]]]]]]]L^R^^^`a b(brc{ccceeeeg+gghhhhhkktl~lZncnoooooopppppppppprqwqqqLrOrs#stt.t5tvv || }}F}L}~~4<=NBHJPU^/6qwՈًƌ؏,;<FkhnߡR`nǥ:FwĬ+5ԭڭǯЯׯܯ !0?@Jopr $ ɵϵ͸Ѹμռ5Xac(AgHQSZY` ]a&*vKR ]gimp~ @AE'(E^rtz:;),msA K !!H!M!!!!!."4"u"""#C#J###%%q%u%''99&:(:F<L<??CCEEKKM"MTTUU$]^]_]{]]]L^^iihnmnoo5t6t||؏"<ǐ16CG ǯ &@˰"]^e'5e78v}6=XbFGwx @AE333333333333333333333333333333333333333333333333333333333333333334I  PbEFj}z4c#$%%&&6**99;::w==,AFA~AAADBEBYBJJNNQQRRUUmhh j,j nPnrXr,u>uwJxxx}},]*g~N&8Õ*6țݛdé)4d.W,-U >@AE @AE2H) $j9hxt^{0~|bJB5{+!a#C4k}$(l&%N2/BR7$#X6B5Cv@QU7qWX[yeb\ڎNn=QFv=Q\zo| h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHvh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHvh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH^`CJOJQJo(^`CJOJQJo(pp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`OJQJo(hHvh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHvh^`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh[[^[`OJQJ^Jo(hHoh++^+`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hH^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(~{+a# \zQUo|5CebX6B^W5R7J2/2KNnFv) KX[xtl&%}$                                                                                         ):/3B_Af,AcGq<1 Ic<jYyG,Zk_pW"*"l=JlN k{;&,=|M`JpCq5,rkHhyrEsKHbT&0"Cq@+TLR4'.>?XhDV::jIUb%VXuqH ^Z/# &W0:TBdsC6K4RU`{pUqssn8~3^Z/EK!\?pv4OZ-rV`3kz-v44c;BPWON^Cqa|er'|/Cohok(o]B B:T8{K@%O-{OhC.<OXn(xP)-\}^9L dd@p=@(pka_QfP4 AwzQ/C^i W '5b "lT~*  $Kdd 1(BH?'F1c_QnsCtRvzv{ _1] Pq!-\W~b%3twvw jER2c-P0: I,Qbe/T7Jl`U(Dw`=$Xk gh7JlCj:Tk,u~#9Jd3*h L?^@ji4]y"' #wDX ~&g2 Ls< R:A b=mW9H k] ` \g 'X5i e[q K W.` 9&c F R2~  kA,! l"P Wj ,Zk,9w& I2 T5 -dxD 2*Yu`M r3":O $hfUq *&R7Ei5yG*&rWzbe<H*,)0E/(k3x@izUc<* !\'d b%m!?k]fsje$M"l}U~qB)83AnX^w-6m$l7dH=Ggux;&a"6/ D^d4p0f;!5fk8pblW8+7`M,EhySg~HEp3U6>}U JKQFus[3&4._ ddFo:[gjIb_3/']|3 aBOOM| .Od9'S K]D%yN8Zz} ddlf>kr>}{9&{OG2QVpOM L )9dIbA[-I_PjDt~4p" M,C/T:+8ph ?ywddX]dD},$ 2wj]$beW.$3~H;>;hKGbeJd/NYT 2U Bf* _t de%tX??ahTcJ#0.S k@_UNA@G?^ozg^'em$oV L%gspt @r=A$c]1.-\08lW=[ZrCh1e^LpR~A{( %gIJP9g~XhEE*&|| n8Z< ;^Z//CiL2pR|M`T[cx|SwinB;! xt{iN 5Abef;&lX[ &Brbek-k%{*&n{3XS KuoR?#u$-zdd5.S!zjLOUn7rrV&BrwY$hb#( CH|-JDH^;&]` D.]o"424 Cq=]> 31}bxz} dd?Oy?6 7W'Fe]_QR2@ n _Ndy4ynmolgrn1R,2*YugGV#g9beXp |' `,M|YR]m$ :?+ kg0BDwIj!<[C9@yq;=`;6beL=v?Y$x(?x mpxAW\(RLOUtvw=-x$}FLvW<:X8dd3 C-]"qTMz&vpW}j.}HTTL H;&'r 3 Ko\ W\(8p"7%uv1c,5Hv!Y6dZ<v|fvv){n{<[vC?p8g8=<f~&)BT|?MNdyKZi6aMxV}Y"iYkPz=+0eMG?8T) {zH 9xFUZ\o$4(iF ,2tl>Kdd g4Rs~5d;>IqjTVbNXl}IwZ<}-\vhL>D-V-^iy_ BK]H=G iB'r-;!t `*b^w `*b^] ]Q7!- u#Ml /p OM Ls 4(+~ "2;{ UMZi 4tlO \ k OM Ld> r}Q F ._ 4!< | pW ^Z/4!mC!6X!;$$!*&O59!f,Ai:!mU!] (]!8TOr!&"!^is!/C-!f.\N!l!_1!be"R?#" "u5L$"^GKdd 80)"3qW^yK-"l#40"L?2" KA="]K"cJM"rEsO\_"a"Hz"fj(r3"Y".b "Mr"lB e""|]" \h#c>sT##. Q#f.\GV#7/ye#^Z/###E#!< :#@#R?# $=$vu5L$qT$-T V$IbKZ$m$kY U$}Iw;$Xjs$v?^%$ lIxH$iy_ lG$4~ A$Cq'r$b$B) R$i:!^$Zbp=$u(u( %I%OO%kU!%jIUe&% E%nWEI%pWnCM%9&}%-TB%`%#5%~%rEs>_%{iiA&249&~& ddz&Cq6-)&B!(V'^@(mj0~f(s[fj(=A$jy(A(f,Af(H=Gk(1 ('@@(;-mz(wzke(m$rj(t(p {,)eAdw8)iy_ o.n)eJ)ke(#)< )-/_w)c)WAo5)`*b^I)6)lCg4)KGB^*tvw5 n*re5r*h*N 5W*(*de%*.,\*|87!j*g4S(+&Br_6+xV}*H+k,u&Y+b%^a+_d+`dHAFx+ MS,EEEEEEF+#)?+Xh3+w-68+?^+ sXR+CqQ,{,xt Z&,jG,EEEEEEh),*&)+,p-,xM,Jdd.,,F,iz2k,wzbo,MXz CNy,}IwA,vpI,oC6kA,"q,qrQKdd P'-lB <- M(- lIx:u5-K=-)G-!\sGi-KOw.=o-)-mC!&-rEsOZ-h;C-f~&dd\k-1[].-gg- i,,-$s!S.HNp..b$.:Z.qw,.P-m#0.R2!v2.[RI.R?#a.SH]XKOw.g.I) ..#y.*&<.^.k`[/D'2H/J/rEs|/fJ/bM/&Br^Z/ /Xd/7/-/TFbI/u U /j0 0&z;Jw) 1U_pz 1r@1I;01>=1"2;W_1bcmm1kY {t11d@sq<171beUc1%1 8 2kA,b2| 02jy(J!2"lD'2<>2LpR~k @2n J2 _%"R23|W20h2g4 E2^@(,,,,J2<2H0a272G(3T63betiD3Y"OW3SW3LDs[3S8?!x35$^302y3C-W#3KQS3 j=3rEs%Z3)SlK3~04t%G24J 4?njUN4Lo "u4J}4[p4374Ndy>4| s4"4D&47` 4W_104?4XZ57N 5z5[/ wR5f,A"X5D+'^5Ei5Pm5Dp55uT5*H+57se>/5):/,5_w)75/ D:[5sJmz55w-65#f 6OM LKe26be A6t'A6N6da6rQ6z} dd"6786^RVoC6z=66066&9n)67 7q7nddI77 7N 7bkf]Q7kU7-=^7)%YMh7~bn7 G|87LKt7<}7>=1j7j7z} dd* 7`%s7~07{Ab7H@888s X8~o 8!\Q=38cT?8W802+^8Y$DVl8f.\zA8L ox8O.[8S08581gi8"`$M8xV}t\8[8: H 9tE9d/N6&9 )9y Ax<9"lh91XNj9"pPL@v9rEsKp9;&\A9}9"C9]Q79`*b^ 9|p9kxc!9 hO>:8AaX :zc \:| +&:b%Y,1:rEs%\M:xV}R:pmy:9: W W:bT7:(^:z} ddc:eJI:| H:rEst:@::::72Kd:3tw"2;vCuE;w '=J;^ :Z;e.d;~r;(;=A$h;{cdz<#<*<!L7>e;>iQ;>S<>0RZ>t>gy>betl> P_>| ?>e>]>|>+^8X>-.'?_Qc\7?dVeMG?uE;^N? (Wwt?@fw?)?,.?L?Vlk!?@ n/?^?=H?@p=?`?S8?SWgGv?Ib?@c@^H @Yhl$@dC y%@\ G9!:@rEs k@(b{@Npr@3@'@@sZ@| H@} J-Af,A0A%HANAkbACq1jA .WAb {PA1y A E%'A}bV&Aiy_ ALA/B cM By~ RBVB8pABLxDB 93Bo3P/BBVNB:20mB5bBiTvo{B:s lB^Z/U`*C[85C@zCI7QvC*<lCrensC)`}dd vC`M %C.gGCmf9C}Iw-JDoG`Y$DLDD5Lq(D jfD>DLqD9gt/ D_U`D`*b^/5jG\ G^9BHP>hCH>MIcIv|g#I-fbI)qtlIFT>tIH=GDwIL0II:Ice\vIbT- IR?#ROJ['Y<J-NJz} ddpt J%cJ"k*J80)"xM,Jxdd&z;J< )T)ZJ IJ IJTl5J~s J/oKq 3Kiy_ 83K%"R26Kvw JKEvPKD-Vh{Ke"GkKi6a{K~F a KABKnt ddK;&VKrC\HK`ZW% L*&OM LhnLr#LW\(D)#L0Lg]lD5LLZ=;L"pPLYnp grLejuL_nS3~L%[LliLpz 1S,Lt7LGkTL@ nzOL!\ MPVMfM"lu#M'M 2wgO6M*&YMB^M>/ cM!joM>}{MUN4{8N?NkA,==NN*& jNoBttNYhElwN;> y~N DFX%yN4yN%uV&N@{N5|eHN sbNnLmNf.\B OB/O?6aBOjIU,DOs4PWO hOEG@iOR?#ccOU`{OOy p~JO^iQO?d[OxPPas:#*P+*P6Mzo3PI2 iYkPH{PPPP1}bR}P4pL~PSW3 PKQz= P{/+QxOpR,Q^NQB|v|DrQ[wGQR,=qrQGrHOQwiJQ;&UQ0QmQq;=KQ'FUQE#*PQiQ(]!n1RZ>R8J ~{R=RrEs R`xR"2;ARYSZ[( S) SKG$s!SY= 9S^Z/+'KSrEs MSu!iSLOUskSbe_nScx|S.]\SSOW3mS`d7Sx84NS"6PS0Y-Se4)T1jAQTCj:TR:iQTH_T'lyT^Z/@JTk-T]Q7T6T` fTxtlT7RzcTyG>xTNdybT8p)eT@hu U<[U}-\`U>LbU*&<cU: I ddxUU=HizU /{U2 ddl`UIU`BgUI%jIUb 7U|' `rUfMx6mUhW_V-iddD-VU-VJV*&^RVj+eVy< $oV`Ut7V1C pI1VCj:TdV[sV4p}bVNt$VQV*V*&Vq;=CW (Ww.aWc@ C W!- 2OWT#`ZW@ npWozu|W>xWxOpW$iW*&(WH=GeW!?G4Wp&XSW3DC=1)Y_m b#w_9<_MjU_=^7_3~Le8_5[ _|' `1`OM L$`SI)n`[w\v`^Z/d`/ D`XZ5"`Xw`yu`'T`$h!`Cj:TW`B^*oG`|M`9&$#`k`8Aa+n~F aH0a`jJaKG]lSaas#|aOM L'aNt[asaJ-A%a| Qaz} ddax%~m b ]Ibq;=TVb2[-  lbt:uybtZb5 bJj1}b<!kb5b{AbIb1(\`c-fbI_fGcfhTc?Aaczlc"bcQ=38kc$3Fc*&zcRcc/ D1c2*Yujc$skxc9&{cOc_1ce4w&0cPm5Ic#cjk'iYd\L=df,AeAdH 9#9JdOF J[drEsZ_dzX?dR]`d| ]dJ}4d2(IgzRgPWONWgbeSWgkxc$]gt\8gg Ahg|_hg7JOgWlg(q  kgg#gF+O h| f'har?PNhlB `h| ^xch/ Ds~xh<[UhP>hp..hho$qhhq'hex+h9&rCh;>;Yh*hhz('dhSjHddsyh$s!Sh@h iyMi-+4Ri1s]iOM L*_ibe3_iQ~diq;=phiMj.inB'it77iCqbiR?#ji7Rz{iiKaibe^i lbSi+~ 6_jf= l9jCq7{Gj2U-lMj`3k4=Pj:A +\j-!j04-Fj^Z/?nj` Jj\*!zj`j~HXjMjqlYQj#ogj83Kpxjb8<}lDk!(+n>4+nvmXt=n$nAdrg#I>krvzv&BrsUl~6[sG,osnts{iusCqgssX=m:sAnrEsbs$sasd@s'tr8pKdd jtS{t;|teMtD Nt<9At"l2tbext:s$ccccWtv~t)Bnt9gtxtuXFu2*Yu$V,,A.tuvuWt ulu%'u0>{&u8u02u(urj(%uFLv-JDvv)8v?ywdd~VDv5C>Jvm'jv,MlvB|vTv'BX8\vQpv%uvK=-zvNdyrv^Z/lv 2w 2w'BXe4wsJmoOw}Iw (WwTv&kwb%aww]Q7}Iw%w4?yw[wmm1qwFkw` `w2[- wR?#w3tw<2w"lM xIJKxY$xb2T|!joM"|a|cx|S?k}{&un}.SxV}b8<}IF}GQ\}IF})`}H[-`}\08z5n}s4}>BH^9}aww.z}&0cXmb}H1}X8dd?y}^z}^}@~L~e`!~i-~^RVLpR~t%GUl~bBRs~T~\>~a(|Cg~J)x%~:TB!~y~`xR,S~ E2 ~},h^LR}IwN~Cq&Brh_r@z@#@VKXPn-2I^8k j &I/2DDqn`rht!,W>2?I|Q UOf.iW1';SzT 9*y,^AJOZbbeu>WHYlSrA;3&(J14X<v@Ej #+PHUg:yz` tK(B38@b)Ax\jfzm|  $  t? D o u x ! ' Q I\ lj P  + , F  . Ob!7BMj/rs &]Kk  @% Jbcjtpv{X]&{& 6HyttXvvQ" f(M9qEY_xh{ s(67jBPT]| &U&U(/%02TU&W ggpj"w3K!?#2$64kl *_)6BFP`j  4;pIKNKmv/7KaZcup}"(?GK0PP)i[ =G'iw 73AgMXakkrw2#=@EFI ZGe v #n.CFNQ\&i4nt}S5=OPZBd& ZC I Y \ _ p ;~ !!#!8%!4!<:!%H!W!b!d!"%"/"x7" 8";"`Q"["a"8m"q"r"6t"w"#$#d+#Y,#1#d#[j#$ $!$F$RR$`S$t$y$e}$ %#%%Q$%(%2%z<%0>%(I%O%DS%V%Z%&C&M&x&''L<')D' X'\j't'<((4(k7(V(Y($[()k)3)J")<)MB)Y)Z)\)a)d)q * *#**4*>*+7+)+B8+H+Q+4X+/f+S+@ ,",1,65,GJ,Q,j,|,-U -"'---I-Y-^-7q-Z.R.~'...0.2.9.S._.Kg.///$///J/^/ua/k/x/~/0? 0F00;!0R#0 (0i00y60?0+E0E0wF07b0p0~w0Zy0|0,}0D 1D 1!1&1H1 N1e1Ol1rs1z1`~182p2o2222$20W2h2s2#3 3F 333"J3$v3H4#4#14s7494I:4<4r[4_4q455j5=55+5G5R5T5TY5l5z5\~5 6 6 6\6G6S6^6a6np6c{6.#7z)7c67r97'@7gP7Q7j72x7;~7< 888$8?A8a8e8j8~ 9:9;9a<9F9O9O9^9d93k9$:)0:4:E_:Rt:.;:;B; L;P;U;p;v; <<1 </<4<t;<@<K<N<X<:\<Yd<Ci<r<uy<f==+=-=:===qC=@O=R=i=b>P>7>0>f>j>r>?????P?b"?"?&?++?G,?A?I?b?x?@+@-@O:@HU@UU@`@g@~@iA-ADA)[A^AiAt3B%;BCBLBMBqNBWPBaUB]VBcBklBC CdC C%C*C2C5CHCRCUC sCzC+D&D )D+D:D)BDKCDCDCDJD_DE`DcaDaDzDDSEEE EAE7EEMElVEn^E{bEFFF-FEOFATFXF`FcFnFsFMG7)G+G,Gy9GjG6nGpGuGHH>HH!H#H66H=WHXH_HiHuH{}HJIIV'IZ*II+I0I2IQ4Ib7IL>LGLHLNLWLWLXLM]M&M>MUMaM~MNNNNTST^TmvTSzTUUUUP4U)>U^U Ve V Vy4V6V@=VLVLVQVgVDpVGyV}VWWR WU4W*:WXEXMXnX~X Y YY"Y*Y6YH;Y;YEWYdY9{Yi Z;Z?WsWrstsws ttt,tm2tHtXtitjt/rtrt}~tuuu\u u!ug"u2uC3uN8u8uj:u FuHu IuZuHguBhuhuyuvQ vv!v?%v5v9vAv4Uvdmv vv|vwwxw+wIwXwxxx"x%x}:x=xKxzx1 y)yCyay zazmz,z8z?zGzNzPzZzezwz${&{X*{3{"8{e:{J{]{h{s{||||sU|c|/}}1}#}3}3}b;}<}P}U}]}*f}q}"~~o~~ ~!%~]~a~h~x~_S0dZpIPV e]hks}w$$-F05ST^X_Zjz/+B@Avt4Y7>C|VWd/6rW[.w44Wswj#x7x=H Q>nM\IfWkm/:@%s36?JQ,eglnr)34CI  \O46!^'Deiqe%'9Fb\iZvV}]612RD_JKIX^\clY"Wg,nr}  Jw#%N'Lbt"3?V yZ#6MTwV]~"CUDVV Wknr= <#tUAjot+ 8bV)$&:ORccqrtN'78<8Yjk: D79<<IUYg\vPxp 4,J\"_l&C (Nj]giwr|v~ M5&*^tw "rh-O6Zs t'8:6D~SdqK *#<=PS0Ti`&qkp+26@I.Qv(<(39?A!H L`NSmyoqq^s 036bIdjnn<e>?@0`nru[{@~hi\ui6:/GM^yB157{89:>CETj'<F6mP5 >]f]cl)wx*'V\Cahx&1O47\<>UCov-:,`1RX8Z[]Mf)_ '175CEoOo|)5GGe_M %I35>HNNyU&]DGVa}><'=G&HJs(g8H(/s39JpPQSEi{ 2v/0t8^eklWr v '*/Flyt{] /|56CR6Xlilqh"7d9i kmns(R<`z~xQ"f*0]:CCQqu+8pIPW- r/1\=EII#t|}C0<G,UAt 6")8::T]8qs^}W< N+;6:&;'Gfm~~OP8]but ~GTUn\^bcosu!{t~#)M7\bx}lT"6_lmw{7|& A_r3|J7TU`A|&=OcZ<;%>FI$'/6DFU^#efwi~o%&7'<LTSS b b.oz5  @!,1'Pddq5R8I?A_e|G !eBKLC[r8B2auuyz $,.NHWvvm'5:AMNN[pHqT s K#f;?f{* 'G6.IVVZ ]^48<5L;XgzT\ YJ$O9<CUT;kmo!p/ Ld$F'G>WYd4iIrVr|n -7<BEN^ a 4W'+,6K>_>g>??AUMTUEYvYf7pXz g >F M VWb  X66=NV^1t|!#'O* y !E"l/Y@CCJKe`n (#+ 799"<rHHIQV{`In z!--2@[\a bl rC#SE+x-T:'<e:gs3~Qc;op0wi(CEGSSTz&+z 'Y';3=5 8?G kkngw(S.GW\tP -N5RXXq}4 J &: S0gDj%p[q} VW[3]oxqz+58IAR,qt{tkv0(F@chklu~m2H<0&(*[1<56DfOQadjQ34 9<~L}tc,9DI KWi !##%!);k=Eu !'s,|-KQWW; {$$3F9PQW}^jnc14J\s,19EZXuiiV  KAa^M!J%x8 AHVlWX|I"@%fmm v15?mIPV hmrs'>LE[IdKNLs`gr  ( p9!#d2HWPjn 7T`Tg4 6    OPb%&&4'5'^'**9):*:+:,:Ey0y0y0@:;?- ::(owoxDp@pp@Unknown Diana LoschGz Times New Roman5Symbol3& z Arial7&  Verdana; Batang?5 z Courier New3z Times5& zaTahoma;" HelveticaA& Trebuchet MSG  MS Mincho-3 fg;SimSun[SO?& Arial BlackA& Arial Narrow7&{ @Calibri;Wingdings"1hay&k$|k$|$4dݎ 2qHP ?P2 /Audrey s Selected Meeting List for January 2008Audrey Audrey Erbstl                   Oh+'0  4@ ` l x 0Audreys Selected Meeting List for January 2008AudreyNormalAudrey Erbst5Microsoft Office Word@ @,kg@n o@Wɞk$՜.+,0 hp|  |' 0Audreys Selected Meeting List for January 2008 Title  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMOPQRSTUVWXYZ[\]^_`abcdefghijlmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUWXYZ[\]_`abcdelRoot Entry Fp0អnData No81TablekeWordDocumentSSummaryInformation(VDocumentSummaryInformation8^CompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q